

**Copyright Information of the Article Published Online**

|  |  |
| --- | --- |
| **TITLE** | Emerging concepts in alcoholic hepatitis |
| **AUTHOR(s)** | Phoenix Fung, Nikolaos Pyrsopoulos |
| CITATION | Fung P, Pyrsopoulos N. Emerging concepts in alcoholic hepatitis. *World J Hepatol* 2017; 9(12): 567-585 |
| URL | http://www.wjgnet.com/1948-5182/full/v9/i12/567.htm |
| DOI | http://dx.doi.org/10.4254/wjh.v9.i12.567 |
| OPEN ACCESS | This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| CORE TIP | Current research of alcoholic hepatitis patho­physiology *via* translational research has provided insight to novel therapeutic options. Recovery from severe alcoholic hepatitis with assistance of gut microbiota modification, immune modulators, stimulation of liver regeneration, caspase inhibitors, farnesoid X receptors, and extracorporeal liver assist device may be promising. |
| KEY WORDS | Immune modulation; Alcoholic hepatitis; Gut microbiota modification; Extracorporeal liver assist device; Apoptosis inhibitors |
| COPYRIGHT  | © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| NAME OF JOURNAL | World Journal of Hepatology |
| ISSN | 1948-5182 |
| PUBLISHER | Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA |
| WEBSITE | Http://www.wjgnet.com |

REVIEW

Emerging concepts in alcoholic hepatitis

Phoenix Fung, Nikolaos Pyrsopoulos

Phoenix Fung, Nikolaos Pyrsopoulos,Department of Medicine, Division of Gastroenterology and Hepatology, Rutgers New Jersey Medical School, Newark, NJ 07103, United States

Author contributions: Fung P reviewed the literature, performed the majority of writing, and prepared the figures and illustrations; Pyrsopoulos N designed, co-authored and revised the manuscript.

Correspondence to:Nikolaos Pyrsopoulos, MD, PhD, MBA, Associate Professorof Medicine, Chief of Gastroenterology and Hepatology, Department of Medicine, Division of Gastro­enterology and Hepatology, Rutgers New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, United States.pyrsopni@njms.rutgers.edu

Telephone:+1-973-9725252Fax:+1-973-9723144

Received:December 5, 2016 Revised:February 21, 2017 Accepted:March 12, 2017

Published online: April 28, 2017

**Abstract**

Severe alcoholic hepatitis is implicated as a costly, worldwide public health issue with high morbidity and mortality. The one-month survival for severe alcoholic hepatitis is low with mortality rates high as 30%-50%. Abstinence from alcohol is the recommended first-line treatment. Although corticosteroids remain as the current evidence based option for selected patients with discriminant function > 32, improvement of short-term survival rate may be the only benefit. Identification of individuals with risk factors for the development of severe alcoholic hepatitis may provide insight to the diverse clinical spectrum and prognosis of the disease. The understanding of the complex pathophysiologic processes of alcoholic hepatitis is the key to elucidating new therapeutic treatments. Newer research describes the use of gut microbiota modification, immune mo­dulation, stimulation of liver regeneration, caspase inhibitors, farnesoid X receptors, and the extracorporeal liver assist device to aid in hepatocellular recovery. Liver transplantation can be considered as the last medical option for patients failing conventional medical interventions. Although the preliminary data is promising in patients with low risk of recividism, controversy remains due to organ scarcity. This review article com­prehensively summarizes the epidemiology, patho­physiology, risk factors, and prognostic indicators of severe alcoholic hepatitis with a focus on the current and emerging therapeutics.

**Key words:** Immune modulation; Alcoholic hepatitis; Gut microbiota modification; Extracorporeal liver assist device; Apoptosis inhibitors

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

Fung P, Pyrsopoulos N. Emerging concepts in alcoholic hepatitis. *World J Hepatol* 2017; 9(12): 567-585 Available from: URL: http://www.wjgnet.com/1948-5182/full/v9/i12/567.htm DOI: http://dx.doi.org/10.4254/wjh.v9.i12.567

**Core tip:** Current research of alcoholic hepatitis patho­physiology *via* translational research has provided insight to novel therapeutic options. Recovery from severe alcoholic hepatitis with assistance of gut microbiota modification, immune modulators, stimulation of liver regeneration, caspase inhibitors, farnesoid X receptors, and extracorporeal liver assist device may be promising.

**INTRODUCTION**

Alcoholic hepatitis (AH), is one of the most severe manifestations of alcoholic liver disease. It is a public health issue and worldwide disease associated with high morbidity and mortality. Complications related to alcoholic liver disease result in costly hospitalizations. Current treatment strategies are limited. Abstinence is the first line treatment, however may not improve outcomes in patients with severe AH, defined as discriminant function > 32. The mainstay of therapy is corticosteroids, which have limited efficacy in specific populations. Pursuit of new treatment options for alcoholic hepatitis is the holy grail for patients ineligible or refractory to corticosteroids. The judicious use of early liver transplantation for severe alcoholic hepatitis has been explored although medical and ethical controversy remains. Exploration of maximal medical management with microbiota modification, immune modulation, liver regenerative factors, farnesoid X receptors (FXRs), caspase inhibitors, and extracorporeal liver assist device (ELAD) may be promising for patients with severe alcoholic hepatitis who do not have other options.

Sixty percent of the United States’ population reports alcohol consumption[1]. Approximately 8%-10% of the United States population reports heavy alcohol use, which is defined as ≥ 2 drinks daily in men and ≥ 1 drink daily in women[2]. One standard drink contains approximately 14 g of alcohol, which is equivalent to 12 ounces (350 mL) of beer (4%-5% wt/vol), 6 ounces (177 mL) of wine (8%-10% wt/vol), and 2 ounces (59 mL) of hard liquor or whiskey (45% wt/vol)[1]. There are progressive and co-existing stages of disease in chronic alcoholism including steatosis, steatohepatitis, fibrosis, and development of compensated to decompensated cirrhosis. In a study examining hospitalized heavy alcohol drinkers with and without alcohol withdrawal, liver biopsies reveal steatosis in 44.9%, alcoholic hepatitis in 34.4%, liver cirrhosis with superimposed alcoholic hepatitis in 10.2%, and cirrhosis only in 10.5%[3]. In other studies, approximately 20% of individuals with chronic alcohol abuse are found to have AH when biopsied[4].

Alcoholic hepatitis is an acute-on-chronic presentation of liver disease with a wide ranging spectrum of mild to florid, life-threatening injury[5]. It is a clinical syndrome associated with recent onset jaundice and coagulopathy in a person who has been a heavy drinker usually for more than a decade[6]. Although long standing alcohol abuse appears to be associated with the development of AH, the exact trigger for development is unclear.Other factors, such environmental and genetic variables may play a pivotal role. The amount and duration of alcohol abuse needed to produce alcoholic hepatitis is variable depending on the individual patient. Alcohol consumption of approximately 40 g daily for women and 50-60 g daily for men is recognized as a minimal threshold amount for patients at high risk of developing AH. Alcohol consumption is usually within less than 60 d prior to onset of jaundice with heavy alcohol use for more than 6 mo for severe alcoholic hepatitis clinical trial inclusion criterias[7].

It has been reported that chronic alcohol abuse and binge drinking are associated with development of liver disease[8,9]. Binge drinking is defined as five or more drinks in men and four or more drinks in women within a period of approximately 2 h at least once a week[10]. Earlier studies implied that weekly binge drinking may be more deleterious than daily consumption of alcohol[2]. More recent studies suggest daily heavy drinkers had increased mortality from liver disease compared to binge drinkers[11]. It has been reported that the combination of chronic alcohol use with a binge drinking pattern may be more detrimental as animal studies showed mice with chronic ethanol fed diet with an addition of single high dose ethanol administration expressed more severe forms of liver injury and steatosis compared to animals with chronic ethanol feeding alone or single high dose of ethanol only[12]. Further studies are needed to delineate the pathophysiology of binge drinking and its’ effects on alcoholic hepatitis.

The true incidence of alcoholic hepatitis is unknown. Based on Denmark studies from 1999-2008, the annual incidence rate of alcoholic hepatitis was 46 per 1000000 in men and 34 per 1000000 in women[13]. In the United States, alcoholic hepatitis accounted for 325000 ad­missions annually in 2010 with average hospitalization cost of $46264. The most common admitting diagnosis for patient hospitalized with AH was hepatic encep­halopathy[14].

**PATHOPHYSIOLOGY**

The pathogenesis of liver disease related to alcohol consumption is not completely elucidated. Most studies simulating alcoholic hepatitis are recreated in animal models using an alcohol and fat infusion method[15]. The etiology of alcoholic hepatitis is complex and multi­factorial. Principal factors include steatosis, oxidative stress, altered gut permeability, toxic metabolites, and formation of cytokines result in the initiation of an inflammatory cascade.

Ethanol is oxidized by three metabolic pathways: (1) alcohol dehydrogenase mainly; (2) cytochrome P450 2E1; and (3) catalase (Figure 1) Ten percent of ethanol oxidation occurs in the microsomal cytochrome P450 CYP2E1. Ethanol catalase driven reaction in the liver per­oxisome is negligible[16].

Ethanol is metabolized into acetaldehyde *via* the cytosolic alcohol dehydrogenase enzyme within hepato­cytes. Acetaldehyde is converted into acetate and reduced nicotinamide adenine dinucleotide (NADH) *via* mito­chondrial and cytosolic aldehyde dehydrogenase[17]. NADH is increased as a byproduct of ethanol metabolism. Elevated NADH/NAD+ levels inhibit gluconeogenesis and fatty acid oxidation and is responsible for the high amounts of acetyl-coA found in heavy alcohol users[18]. Acetyl-coA induces fatty acid synthesis by serving as a precursor for fatty acid and cholesterol biosynthesis[19]. In addition, ethanol inhibits the peroxisome-proliferator-activated receptor  and adenosine monopho­sphate activated protein kinase with stimulation of sterol regulatory element binding protein 1, a membrane bound transcription factor to promote lipogenesis[20-22].

Acetaldehyde is direct hepatotoxin and a known carcinogen[23]. Acetaldehyde form adducts that are potent immunogens to activate inflammatory cytokines[24,25].The production of reactive oxygen species inducing lipid peroxidation with additional cytotoxic effects of ethanol metabolism induce hepatocyte necrosis[26]. Damage-associated molecular patterns are produced after cell necrosis, which trigger inflamma­tion, fibrosis, and abnormal hepatocyte regeneration[27]. After chronic ethanol consumption, the activity of the microsomal ethanol-oxidizing system increases by 5-10 fold, with an associated rise in cytochrome P-450, CYP2E1. CYP2E1 metabolism increases reactive oxygen species and acetaldehyde production, which diminishes hepatoprotec­tive reduced glutathione and other defense systems leaving hepatocytes to be more vulnerable to oxidative stress[28,29].

The endoplasmic reticulum (ER) regulates protein folding, maturation, misfolded protein degradation, and regulation of new protein entry[30]. When proteins are misfolded in the ER, the unfolded protein response is sensed by the binding immunoglobulin protein/glucose regulated protein 78 (GRP 78). This reaction produces oxidative stress and disassociation of the endoreti­culum transmembrane transducers. The transducers are responsible for the activation and recruitment of c-Jun N-terminal (JNK), a stress kinase[31]. Multiple mechanisms, including downstream inflammation and increased oxida­tive ER stress from hyperhomocysteinemia activates nuclear factor kappa beta (NFΚΒ) and JNK to induce hepatocyte apoptosis *via* caspase activation[32,33]. De­ficiencies of B vitamins or homocysteine metabolism mutations seen in chronic ethanol use cause accumula­tion of homocysteine, which induces the ER stress of the hepatocytes and vascular endothelial cells. In addition, ER stress is associated with fatty acid synthesis *via* the activation of SREBPs (sterol regulatory element-binding proteins), which enhance cholesterol and triglyceride biosynthesis and fibrosis *via* stellate cell activation[34,35].

Ethanol induces gut dysbiosis and alters the per­meability[36]. Increased gut permeability allows the endotoxins to infiltrate the liver through the portal vein[37] (Figure 2). Endotoxin levels are measured to be high in patients suffering from alcoholic hepatitis[38]. Bacterial lipopolysaccharide, an endotoxin, binds to the lipopolysaccharide binding protein to form a complex. The complex latches to the CD-14 molecule to activate Kupffer cells and macrophages *via* the toll-like receptor type 4 (TLR-4)[39]. This reaction stimulates mitogen-activated protein kinases [such as extracellular signal-regulated kinase (ERK-1/ERK-2), JNK and p38], NFΚB, and activator protein 1 (AP-1). Reactive oxygen species produced by Kupffer cells cause the recruitment of adhesion molecules [intracellular adhesion molecule 1 and vascular adhesion protein 1, chemokines (IL-8 and C-C motif chemokine ligand 2), and inflammatory cytokines (tumor necrosis factor-, IL-1 and IL-6)[40]. The enhanced in­flammatory T-helper-type 1 (TH1) response to alcohol dehydrogenase in alcoholic hepatitis induces additional neutrophil recruitment[41,42]. Nicotinamide adenine dinu­cleotide phosphate-oxidase (NADPH) oxidase is an additional contributor to ROS[6]. Pro-inflammatory cytokine, IL-17 induces the migration of neutrophils into the hepatocytes and stimulates the hepatic stellate cells to produce IL-8 and chemokine CXC motif ligand 1 (CXCL1), which recruit other chemokines to attract other neutrophils[43]. IL-22 is stimulated by increased levels of IL-6 and TNF-. Although IL-22 is produced by TH17, TH22 and natural killer cells, it’s receptor is mainly found in hepatocytes. It has a hepatoprotective effect against liver injury and secreted in parallel, to counteract the effects of IL-17[12].

Peripheral neutrophilia is a characteristic finding in alcoholic hepatitis[44]. Normally, neutrophils are re­cruited to aid in tissue repair and recovery[45]. The innate immunity is impaired in patients with progressive liver dysfunction, contributing to multi-organ failure seen in patients with severe alcoholic hepatitis. Serum analysis of acute alcoholic hepatitis patients compared to patients with alcoholic cirrhosis and healthy controls show a significant reduction in antibacterial innate and adaptive immune responses. An impaired T cell response from AH patients produces fewer interferon gamma when exposed to lipopolysaccharide with impaired neutrophil phagocytosis and defective monocyte oxidative burst when stimulated by bacterial challenge. Defective monocyte oxidative burst reduces the expression of NADPH oxidase, which is responsible for generation of superoxide radicals required for bacterial killing. Higher rates of infection in AH may be explained by this impairment[46]. The T cells of AH patients exhibits increased numbers of PD ligand 1 (PD1), T-cell immunoglobulin and mucin domain 3 (TIM3), and galectin-9, which are ligands responsible for programmed cell death functioning. The blockade of the PD1 and TIM3 can restored the innate and adaptive immunity by increasing T cell and neutrophil antimicrobial activity[47].

Other aldehydes produced along with acetaldehyde contribute to progressive hepatic fibrosis by inducing collagen synthesis. Collagen production activates transforming growth factor  dependent, platelet-derived growth factor, and independent profibrotic pathways to active hepatic stellate cells, which contribute to portal hypertension[48].

**RISK FACTORS**

Studies have identified risk factors towards the develop­ment and progression of liver disease. Patterns of drinking, gender, genetic predisposition, and concomitant liver disease may increase the risk of susceptibility. Simultaneous alcohol consumption with food intake has been published to lower risk of alcoholic liver disease compared to those consuming alcohol alone[9]. Variant genes encoding for alcohol metabolism, such as alcohol dehydrogenase, aldehyde dehydrogenase, and cytochrome CYP2E1 might facilitate hepatotoxicity by increasing alcohol tolerance *via* delay of acetaldehyde formation or the metabolism of alcohol through other non-oxidative toxic pathways[49,50]. Acetaldehyde dehydrogenase gene polymorphisms may cause varying levels of alcohol sensitivity in Asians and women, who can develop alcoholic liver disease even if they do not consume alcohol as heavily as others. Women are twice as likely to develop hepatotoxicity with lower amounts and shorter duration of alcohol use compared to men, which may be attributable to gastric alcohol differences and higher proportion of body fat in women in addition to differences in dehydrogenase levels[51-53].CYP2E1 gene polymorphisms can affect the metabolism of alcohol amongst those with different ethnic backgrounds and alcoholics, however the exact pathogenesis is yet to be eludicated[54].

Variations in patatin-like phospholipase protein 3 (PNPLA3) has a strong association with cirrhosis develop­ment in Caucasian and Mexican patients with alcoho­lism[55]. Patients with G allele of PNPLA3 have a higher risk of steatosis and fibrosis, as well as a significantly higher prevalence of alcoholic cirrhosis compared to those with C allele[56]. Recent data published from a genome wide association study found that severe alcoholic hepatitis risk is associated with PNPLA3 rs738409 variant, which until recently has been associated with cirrhosis development. Identification of SLC38A4 variant gene is another novel independent risk locus for severe AH[57].

Caffeine consumption may have a protective effect against development of AH. Recent studies by Chalasani *et al*[58] found the risk of AH was 27% with heavy alcohol users with PNPLA3 genotype CC with regular coffee consumption compared to 86% in heavy drinkers with PNPLA3 genotype GG, who did not consume coffee. PNPLA3 CC genotype subjects who were not regular coffee consumers had a 48% risk of AH. The risk of AH with PNPLA3 GC with and without regular coffee drinking was 37% and 62%, respectively. The risk of AH was 57% in patients with PNPLA3 GG gene who were regular coffee drinkers[58].

Underlying obesity with body mass index (BMI) ≥ 30 likely potentiates the severity of alcoholic hepatitis. A common pathway is postulated for the generation of steatohepatitis through synergetic or additive effects of heavy alcohol use combined with obesity, although the exact mechanism is not well defined[59]. Diehl *et al*[59] published a paper documenting a supra-additive interaction between obesity and heavy alcohol con­sumption. One unit of alcohol was equivalent to 8 g. Overweight or obese male subjects who consumed 15 or more alcohol units per week had an increased risk of liver related morbidity and mortality compared to controls. Another United Kingdom study examining 107, 742 women found that subjects with high BMI (≥ 25kg/m2) who drank ≤ 15 units of alcohol have an equivalent risk of chronic liver disease development compared to women with low BMI (< 25) who drank ≥ 15 units per week. Women with BMI ≥ 25 who drank ≥ 15 units of alcohol weekly had the poorest outcomes. Even in overweight women who did not drink alcohol, the risk of negative outcomes were present[60].

Alcoholics with other liver co-morbidities, such as hepatitis B, hepatitis C, and hemochromatosis have greater disease severity and likelihood to develop cirrhosis[61,62]. Underlying chronic liver disease may contribute to the development of acute-on-chronic presentation in AH.

**HEPATITIS B AND C WITH ALCOHOLIC LIVER DISEASE**

The prevalence of hepatitis C patients with alcoholism is approximately 16% compared to the 1.5%-2% pre­valence in the general population[63,64]. Patients with concomitant hepatitis C and alcoholism have 2- to 8-fold increase risk of all-cause mortality compared to patients without hepatitis C[65]. Alcohol abuse reduces survival in patients with hepatitis C, especially in women[66]. Hepatitis C viral load was significantly increased within 4 mo when patients had higher amounts of alcohol consumption of 39-100 g/d compared to 0-50 g/d[67]. Alcohol induced liver fibrosis in patients with hepatitis C is dose-dependent and exhibited patients who ingest 30-40 g daily[68]. Mechanisms of the synergistic hepa­totoxic effects of chronic alcohol abuse in patients with hepatitis C include altered cell-mediated immunity, increased oxidative stress, increase viral replication, hepatic steatosis, and inflammatory response from iron accumulation[62].

Studies on viral hepatitis and chronic heavy alcohol use are mostly in patients with hepatitis C. Mecha­nisms of pathogenesis can also be applied to hepatitis B patients. Hepatitis B or C drinkers have an increase risk of hepatocellular carcinoma compared to non-drinkers[69,70].Alcohol use did not effect viral efficacy in hepatitis B patients treated with entacavir or hepatitis C patients treated with interferon, however alcoholics may be less compliant with medication adherence[71,72].Elevation of liver enzymes induced by alcohol can cause overtreatment of patients with chronic hepatitis B. It has been published that only 50% of patients with aminotransferase elevation was caused by immune active chronic hepatitis B among other etiologies[73]. Iron deposition is found in > 50% patients with chronic hepatitis C or heavy alcohol consumption, which is not typically seen in hepatitis B[74].

**HEMOCHROMATOSIS WITH ALCOHOLIC LIVER DISEASE**

Hepcidin is a peptide produced in the liver for delivery of iron through the ferroportin transporter. When hepcidin levels are decreased in patients with progressive liver disease, iron is accumulated in the hepatocytes[75]. Concomitant iron accumulation and ethanol toxicity may be associated with increased production of oxidative stress. Patients with hemochromatosis who consumed more than 60 g of alcohol per day were 9 times more to develop cirrhosis than who consumed less[76]. Elevated hepatic iron concentration is associated with higher mortality in alcoholic cirrhosis patients[77]. Iron accumula­tion seen in alcoholic liver disease and hepatitis C is independent risk factor for hepatocellular carcinoma development[76]. Fifty percent of patients with hereditary hemochromatosis develop fibrosis with a 200-fold risk of hepatocellular carcinoma development[78].

**NASH AND ALCOHOLIC LIVER DISEASE**

Patients with risk factors for non-alcoholic steatohepatitis (NASH) are identified with insulin resistance, obesity, hyperlipidemia, and metabolic syndrome in the setting of minimal alcohol use compared to alcoholic liver disease patients[79]. Differentiating between alcoholic and NASH can be challenging as imaging, laboratory studies, and histologic findings can be non-diagnostic. Attaining a careful alcohol consumption history is cardinal, but can be unreliable. Histologically, patients with NASH tend to have more advanced fatty degenerative hepato–cytes, while there is generally a greater neutrophillic predominance and frequency of Mallory Denk bodies in hepatocytes with alcoholic liver disease. Mallory-Denk bodies are misfolded protein aggregates induced from ER stress, which are deposited into ubiquitin-rich cytoplasmic inclusions within ballooned hepatocytes[80,81]. Mallory-Denk bodies can be present in chronic cholestasis, Wilson’s disease, NASH, and amiodarone toxicity. They are not exclusively seen in alcoholic hepatitis[82]. Patients with alcoholic liver disease tend to higher rates of perivenular fibrosis, phlebosclerosis, cholestasis, and ductal pro­liferation compared to NASH patients[83]. Using logistic regression, Dunn *et al*[84] identified mean corpuscular volume, AST/ALT ratio, body mass index, and gender as the key variables to differentiating alcoholic liver disease from NASH patients of Caucasian ancestry. The alcoholic liver disease/nonalcoholic fatty liver disease index (ANI) created was found to have good diagnostic capacity compared other previous proposed biomarkers. ANI > 0 was consistent with an alcoholic liver disease diagnosis, while an ANI < 0 was likely due to nonalcoholic fatty liver disease. ANI is not as reliable in cirrhotic patients with Model of End-stage Liver Disease (MELD) score > 20, as well in patients with concomitant alcoholic and NASH disease[84]. A 20-year observational study of patients with uncomplicated hepatic steatosis concluded that 1.2% of non-alcoholic fatty liver disease patients developed cirrhosis compared to 22% of alcoholic fatty liver disease patients[85].

**CLINICAL PRESENTATION**

Symptoms of alcoholic hepatitis are nonspecific. Patients can experience fatigue, right upper quadrant abdominal pain, anorexia, fever, and weight loss. Development of jaundice may occur in a rapid fashion. Patients with alcoholic hepatitis can develop tender hepatomegaly, ascites, hepatic encephalopathy, upper gastrointestinal bleed, and sarcopenia. Signs of chronic alcohol abuse such as spider angiomata, splenomegaly, palmar erythema, gynecomastia, parotid gland enlargement, testicular atrophy, and Dupuytren’s contractures may be present. Characteristic laboratory studies demonstrate a 2:1 aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio with typical values less than 300-400 mg/dL. Serum ALT levels are typically lower than AST in alcoholic hepatitis due to a reduced ALT activity in vitamin B6 depleted hepatocytes and mitochondrial injury causing release of mitochondrial AST[86]. Higher levels of aminotransferases may point towards an additional factor inducing hepatotoxicity (*e.g.*, superimposed ischemic hepatitis, drug induced liver injury, rhabdomyolysis, or acute viral hepatitis). Bilirubin levels can be as high as 30 mg/dL with severe coagulopathy, leukocytosis, anemia, and new onset of renal failure is seen in patients with hepatorenal syndrome[40,87]. Severe alcohol withdrawal can be a life-threatening when patients develop delirium tremens, seizures, coma, and cardiac arrest. Treatment with hemodynamic stabilization, airway protection, and benzodiazepines are necessary[88]. There is a higher prevalence of patients having alcohol withdrawal in alcoholic hepatitis compared to alcoholic cirrhosis[3]. Multiple electrolytic disturbances have been identified in patients with alcoholic hepatitis, such as hypokalemia, hypophosphatemia, and hypomagne­saemia among others. Supplementation with thiamine, folic acid, and correction of glucose, potassium, magne­sium, and phosphate is recommended[23].

**DIAGNOSIS**

Alcoholic hepatitis is mainly a clinical diagnosis. If there is confirmed abstinence for more than 2 mo or the patient reports less than 4 drinks daily on average, alcoholic hepatitis is less likely. Liver biopsy is considered to a gold standard for diagnosis of alcoholic hepatitis, however they are not considered to be routinely performed for AH evaluation in United States. In a review of 11 randomized controlled trials requiring biopsy proven AH, 1409 of 1668 (84.5%) of the liver biopsies confirmed histologic alcoholic hepatitis with increased diagnostic accuracy of 96% when total bilirubin was > 80 mol/L (> 4.7 mg/dL). The authors concluded that a histologic diagnosis was not necessary for diagnosis and management of AH based on these parameters[89]. Nevertheless, if clinical diagnosis is not clear or appears multifactorial, a liver biopsy can be considered. Caution must be executed when there is severe portal hypertension and coagulopathy. If the benefits outweigh the risks, a transjugular approach can determine the wedge hepatic venous gradient and portal pressures and is recommended when a patient has severe coagulopathy or ascites[90]. Other causes of liver disease, including decompensated alcoholic cirrhosis, sepsis, and biliary obstruction must be ruled out. Abdominal imaging usually shows steatosis and/or cirrhosis with splenomegaly, which is non-specific in alcoholic hepatitis[91].

Cardinal histologic findings of alcoholic hepatitis include ballooning hepatocytes, Mallory-Denk bodies, and neutrophilic infiltration in the setting of macrovesicular steatosis with fibrosis and lobular distortion[92].

**MORTALITY PREDICTORS/PROGNOSIS**

Clinical scoring systems have been developed to predict outcomes in patients with alcoholic hepatitis and guide treatment. Maddrey’s discriminant function, Glasgow score, and MELD score help determine if corticosteroids need to be initiated, while the Lille score evaluates if they need to be continued.

The Maddrey’s score incorporates the serum bilirubin and prothrombin time to produce a discriminant func­tion score (DF). A DF > 32 is characterized as severe alcoholic hepatitis and has high short-term mortality of approximately 50%. Patients with a DF > 32 may benefit from corticosteroid therapy. A DF < 32 is classified as mild or moderate in severity with mortality rate of 10%. Corticosteroid treatment is not beneficial in this patient group[93].

The MELD score predicts mortality in alcoholic hepatitis and survival in cirrhotic patients. MELD score performs as well as the DF in 30-d mortality prediction. Corticosteroid therapy reduces short term mortality in patients with MELD score of > 11 or bilirubin > 8 mg/dL with ascites[94]. A retrospective study determined that an increase in MELD ≥ 2 within the first week of hospitalization is independently associated with in-hospital mortality[95]. A study by Dunn *et al*[96] found that a MELD ≥ 21 has a 75% sensitivity and specificity to predict mortality with an estimated 90-d mortality of 20% for patients with this score. A MELD ≥ 21 can be applied to treatment guidelines for corticosteroid administration.

The Lille score monitors the change in total bilirubin after the first week of corticosteroids to identify the response of patients with severe alcoholic hepatitis. Patients with Lille score > 0.45 indicates poor response to corticosteroids and predicts a 6-mo survival of < 25%. Non-responders are recommended to stop corticosteroids due the risk of infection[97]. Recently, a study showed that Lille score on day 4 was as good as day 7 to predict 90-d mortality and reduces unnecessary steroid exposure[98]. A meta-analysis of five randomized clinical trials with prednisolone treated subjects with severe alcoholic hepatitis showed an improved survival benefit when sub-classified based on Lille score. Complete responders (Lille score ≤ 0.16), partial responders (Lille score 0.16-0.56), and null responders (Lille score ≥ 0.56) has 28-d survival rates of 91%, 79% and 53%, respectively. Corticosteroids had a significant effect on 28-d survival in subjects with Lille score ≤ 0.56[99]. Side effects of steroids include infections, hypokalemia, osteopenia, and weight gain. Fungal infections, especially Aspergillosis are common in the steroid treated group[100].

Another prognostic score is the Glascow alcoholic hepatitis score (GAHS), which incorporates age, serum bilirubin, blood urea nitrogen, prothrombin time, and peripheral white blood cell count. Patients with a DF ≥ 32 and a GAHS < 9 did not show benefit from treatment with corticosteroids. For those patients with a GAHS ≥ 9, there was a significant improvement in survival for patients who received corticosteroids. Day 28 survival was 78% for those treated with corticosteroids compared to 52% for the placebo group[101].

Altamirano and his group published the Alcoholic Hepatitis Histologic Score system in order to predict the 90-d mortality. The degree of fibrosis, degree of neutrophil infiltration, type of bilirubinostasis, and presence of megamitochondria were independently associated with 90-d mortality. The factors identified patients with a low (0-3 points), moderate (4-5 points), or high (6-9 points) mortality within 90 d (3%, 19% and 51%, respectively). The disadvantage of this scoring system is that it requires a liver biopsy, which is not routinely performed in the majority of alcoholic hepatitis patients[102].

Factors associated with increased mortality from alcoholic hepatitis include: Older age, acute kidney injury, elevated bilirubin level, coagulopathy, leukocytosis, alcohol consumption > 120 g/d, infection, hepatic encephalopathy, upper gastrointestinal bleed, and bilirubin to gamma glu­tamyl transferase ratio > 1[103-106].

***Metabolomic profiling***

Metabolomic profiling is recently constructed to identify biochemical markers in liver-related disease[107]. In a study by Rachakonda *et al*[108], metabolomic profiles were able to differentiate alcoholic cirrhotics *vs* severe alcoholic hepatitis patients with 100% accuracy. The features related to the pathogenesis of alcoholic hepatitis were confirmed by several findings in this study. Severe alcoholic hepatitis was associated with enhanced triglyceride lipolysis, impaired mitochondrial fatty acid beta oxidation, upregulation of omega oxidation, and decreased plasma membrane remodeling. Although there was an increase in measured bile acids found in severe alcoholic hepatitis, intestinal dysbiosis was sug­gested due to low deoxycholate and glycodeoxycholate levels. Other changes seen in severe alcoholic hepatitis include increased glucose consumption by the pentose phosphate pathway, altered tricarboxylic acid cycle activity, and enhanced peptide catabolism. Altered levels of small molecules related to glutathione metabolism and antioxidant vitamin depletion were observed[108]. Another study performed by Rachakonda *et al*[109] showed that patients with severe alcoholic hepatitis were found to have higher levels of serum resistin and plasma activation inhibitor-1 levels with decreased serum leptin levels. Levels of inflammatory cytokines, such as tumor necrosis factor , IL-6, IL-8, and IL-15 were higher in patients with severe alcoholic hepatitis. IL-6 levels of ≥ 38.66 pg/mL were found to have significantly decreased mean survival rates[109].

**BIOMARKERS**

The development of biomarkers sensitive to the detection of alcoholic hepatitis can be helpful for prognostication. Selected-ion flow tube mass spectrometry breathe testing was able to identify increased levels of acetaldehyde, trimethylamine, acetone, and pentane in patients with alcoholic hepatitis with underlying cirrhosis compared to those with liver cirrhosis and acute decompensation from etiologies other than alcohol. These biomarkers represent breakdown products of ethanol metabolism in alcoholic hepatitis. Given the small sample size, larger studies will need to be performed for validation of results[110].

Other markers, such as procalcitonin, lipopolysac­charide, liver progenitor cell proliferation, soluble TNF receptor 1, microRNA profiling, and IL-22 serum levels are being studied for clinical application towards prognostication of alcoholic hepatitis[104,111-115].

**ABSTINENCE AND MEDICATIONS TO PREVENT RECIDIVISM**

The most important primary intervention for alcoholic hepatitis management is abstinence counseling[116]. Abstinence can improve survival in patients with alco­holic liver disease by improving histologic features of hepatocyte injury with reduction of portal hypertension and progression into cirrhosis[5]. Two thirds of patients abstaining from alcohol have significant improvement within 90 d[117]. A 30% decrease in survival rate is seen in patients with compensated cirrhosis who continue to use alcohol compared to those who are abstinent[118,119].Continued interventions, such as combination psychotherapy with cognitive behavioral therapy, peer driven support counseling, motivational enhancement therapy, and comprehensive medical care can reduce recividism[120]. Risk of recidivism is as high as 67% to 81% over the course of one year[121].

Medications to maintain abstinence have been in­vestigated. FDA approved medications are disulfiram, naltrexone, and acamprosate[122]. Disulfiram was first approved in 1983[123]. Other agents have been explored due to poor tolerability and lack of evidence to support its efficacy[124]. Disulfram is not recommended for use in cirrhotic patients as the literature describes cases of fulminant hepatitis requiring liver transplant[125]. Naltrexone is an opioid antagonist used to decrease alcohol cravings, however it can cause hepatocellular injury[126]. Nalmefene works in a similar mechanism of action to naltrexone, but does not have the risk of hepatocellular injury and has a longer half-life[127]. Acamprosate is structurally similar to gamma amino butyric acid and is associated with reducing alcohol withdrawal symptoms based on 15 controlled trials. As a maintenance medication, it can decrease the relapse rate and relapse severity compared to placebo[128]. In a recent randomized, double-blind study in the United States, there was no evidence of efficacy for acamprosate compared to placebo among alcohol-dependent individuals recruited from a primary care setting[129]. These patients did not receive extensive multidisciplinary counseling. In the COMBINE trial, there was no substantial benefit for patients treated with acamprosate *vs* naltrexone or intensive abstinence counseling. The PREDICT study is a randomized clinical trial conducted in Germany, which compared its data to the COMBINE study. The primary outcome examined the first occurrence of heavy drinking. PREDICT found neither acamprosate nor naltrexone to supply any additional benefit compared with placebo[130].

There are few medication options to prevent re­cidivism in advanced chronic liver disease. Baclofen is  aminobutyric acid B-receptor antagonist, which is minimally metabolized in the liver. It is one of the few treatments studied in cirrhotic patients. Addolorato *et al*[131] performed a rando­mized double-blinded placebo-controlled in alcoholic-dependent cirrhotics with baclofen 10 mg three times daily for 12 wk in the treatment arm. Seventy-one percent of maintained abstinence compared to 29% in the placebo group. Baclofen may be beneficial to achieving and maintaining abstinence safely in Child-Pugh class A, B and C cirrhotic patients[131]. Gamma hydroxyl butyrate may be well tolerated in patients with decompensated cirrhosis with alcohol withdrawal symptoms due to the short half-life of 4-6 h. Further studies need to be performed before recommendations on efficacy and safety can be made[132]. None of the medications discussed have been studied in the context of alcoholic hepatitis and remains a challenge to medical practitioners.

**TREATMENT**

***Nutritional supplementation***

Patients with alcoholic hepatitis and cirrhosis have nutritional deficiencies and sarcopenia. Protein calorie malnutrition is associated with short and long term mortality[133]. Vitamin A, Vitamin D, thiamine, pyroxidine, folate, and zinc are common vitamin deficiencies seen in alcoholics[134]. Early studies from the Veterans’ Association found 100% of the 363 alcoholic hepatitis patients had protein calorie malnutrition[135]. The degree of malnutrition is associated with the severity of liver disease. AASLD and EASL guidelines recommend enteral nutritional therapy in AH patients, however the evidence remains controversial[2,136]. Moreno *et al*[137] ran­domized 136 biopsy confirmed severe alcoholic hepatitis patients to receive either intensive enteral nutrition *via* feeding tube plus methylprednisolone or conventional nutrition plus methylprednisolone for 14 d. There is no significant difference in the six-month survival between the groups with 44.4% deaths in the intensive enteral nutrition arm and 53.1% of the controls. The study results were likely affected by being underpowered. The mortality rate at one and six months are lower in the intensive enteral nutrition group compared to the control, but the results are not statistically significant. Of note, 48.5% of the patients had the enteral tube discontinued prematurely. Five patients had serious adverse events related to enteral nutrition, such as aspiration pneumonia, hyperglycemia, and hepatic encephalopathy exacerbation. Nevertheless, this study implies that patients receiving < 21.5 kcal/kg per day have a significantly lower survival rate with increased risk of infection and hepatorenal syndrome at 6 mo compared to those with better nutritional rates. Patients with nutritional requirements of ≥ 65 g/d of lipids and ≥ 77.6 g/d of protein have better six-month survival rates[137,138].Further investigation needs to be pursued to delineate the role of nutrition in AH patients.

***Corticosteroids***

Patients with mild alcoholic hepatitis (DF < 32) have a 10% mortality rate when not treated with prednisolone. Supportive care is warranted[139]. Multiple treatment options have been studied, however only prednisolone have remained the mainstay of therapy[91,136]. Cor­ticosteroids have a wide range of immune modulatory functions including suppression of pro-inflammatory transcription factors: NFΚΒ and activator protein 1 (AP-1), which lower circulating levels of TNF- and IL-8[140,141]. Prednisolone use is indicated in patients with DF > 32 or hepatic encephalopathy, but contraindicated in active infection, gastrointestinal bleeding, acute pancreatitis, or renal failure[142,143].

Studies examining the combination of prednisolone and pentoxifylline treatment produced mixed results[144,145] or showed no added benefit of pentoxifylline[146,147]. The Steroids or Pentoxifylline for Alcoholic Hepatitis trial is the largest randomized clinical trial to date, which examined the short and long term mortality of patients with severe alcoholic hepatitis. Results show no reduction in all cause mortality at 28 d for patients treated with prednisolone or pentoxifylline. However, there is a non-significant mortality benefit at 28 d in the prednisolone treated group, which is not seen at 3 and 12 mo[148]. Corticosteroids may have some benefit within the first month, but cannot be generalized to a provide long term value.

The meta-analysis of 22 randomized clinical trials performed by Singal *et al*[90] show a reduction in short-term mortality in patients with severe alcoholic hepatitis treated with steroids *vs* placebo. Corticosteroids with N-acetylcysteine (NAC) compared to corticosteroids alone may be effective in improving short-term mortality[149]. More recently, Thursz *et al*[150] performed a meta-analysis of 9 randomized clinical trials comparing the use of corticosteroids, pentoxifylline, or both for the treatment of severe alcoholic hepatitis. They found that corticosteroid treatment improved 28 d survival compared to pentoxylline and control group. There is no added benefit of treatment with combination group of corticosteroids and pentoxifylline[151].

***Pentoxifylline***

Pentoxifylline inhibits tumor necrosis factor, a cytokine responsible for the inflammatory cascade initiation seen in alcoholic hepatitis. One out of four randomized controlled trials showed a mortality rate of 25% in pentoxifylline treated patients with DF > 32 compared with 46% in the placebo group. The benefit seen was mostly to prevent hepatorenal syndrome[151]. It can be an alternative for patients who have contraindications to steroids or early renal failure, however is not recom­mended as a first line agent.

***N-acetylcysteine***

Oxidative stress produced from alcoholic hepatitis de­pletes gluthathione levels. NAC is an antioxidant substance, which is a pro-drug to the precursor of gluthathione. Moreno *et al*[137] produced a randomized clinical trial of NAC *vs* placebo, which shows no significant difference[129].In 2006, Phillips *et al*[152] found that corticosteroids are superior to NAC for short-term survival. Nguyen-Khac *et al*[153] examined the use of NAC with corticosteroids in a 2011 randomized clinical trial. They found patients with combination therapy have improved one-month survival compared to patients treated with corticosteroids. There are fewer cases of infections and hepatorenal syndrome in the combination treatment arm. Nevertheless, there is no significant difference in survival at 6 mo[153]. Further studies are needed to evaluate the efficacy of NAC.

***Other anti-TNF alpha inhibitors***

Anti-TNF alpha inhibitors, such as infliximab and etan­ercept is not recommended for the treatment of alcoholic hepatitis. Although early pilot studies of corticosteroids and infliximab show an improvement in the Maddrey score within the first month, later studies have shown anti-TNF alpha inhibitors are associated with increased death from infections[113,154,155].

***Liver transplantation***

Liver transplantation may be considered as a last option for patients with alcoholic hepatitis when medical treatment has failed or is contraindicated. Most liver transplant centers require a minimum abstinence of six months prior to donor allocation consideration. Given the donor organ scarcity, the risk of recividism is feared for patients with alcoholic hepatitis undergoing liver trans­plantation[156].

Data regarding the 6-mo rule as a predictor of long-term sobriety remains controversial[157]. Based on a systematic review, there is no difference in early alcohol use in patients transplanted for alcoholic liver disease *vs* non-alcoholic liver disease at: 6 mo (4% *vs* 5%) and 12 mo (17% *vs* 16%). At 7 years post-OLT, 32% of the patients with alcoholic liver disease reports using alcohol. Although comparable rates of any alcohol use are reported in patients transplanted for alcoholic liver disease and non-alcoholic liver disease, the risk of heavy drinking appears much higher in alcoholic liver disease patients[158]. There is a wide variation among post-liver transplant alcohol relapse rates reported in the literature, ranging from 20% to 50%. Heavy drinking rates range from 10% to 20%[159]. The duration of pre-transplant abstinence does not appear to correlate with post-transplant survival[160], however studies for long term follow-up of the graft in patients transplanted for alcoholic hepatitis with continued alcohol abuse requires further investigation.

Mathurin *et al*[161] reports the results of a multicenter European trial which carefully selected corticosteroid refractory AH patients whom were deemed to have a low risk of recividism after liver transplantation. The episode of AH is deemed as the patient’s first liver decompensating event. Other inclusion criteria includes: Close and suppor­tive family members, absence of severe coexisting or psychiatric disorders, and a covenant to adhere to life-long alcohol abstinence. The study reports no alcoholic relapse within the initial 6-mo follow-up period. Three of 26 patients transplanted for refractory alcoholic hepatitis later resumed drinking alcohol: One at 720 d, one at 740 d, and one at 1140 d after transplantation. Despite counseling by an addiction specialist, 2 patients remained daily consumers (30 g/d and > 50 g/d), whereas 1 consumed alcohol occasionally (approximately 10 g/wk). None of them had graft dysfunction[161].

Im *et al*[162] applied inclusion criteria similar to Mathurin’s European trial for early liver transplantation in severe alcoholic hepatitis in the United States. The low candidate acceptance rate (20%) and the high survival rates for transplanted AH patients compared to controls (89% *vs* 11%) is comparable to the findings in Mathurin’s study. Two patients (25%) had alcohol use post OLT. One patient self-reported a “slip” of 60 g and 15 g of alcohol use at day 84 and 260, respectively. Serial urine ethanol testing and self-reporting were negative thereafter. One patient had alcohol relapse, which is defined as: Four or more drinks daily or at least one drink for 4 or more days in succession after liver transplantation. When the subject with alcohol relapse was further analyzed, it was deemed that the hepatic decompensation was not the patient’s first event and the subject had poor insight to disease prior to transplant. Limitations to the study include small sample size (*n* = 9) and short follow-up period (median = 765 d)[162].

A three-year pilot by Lee examined 2 groups of patients selected to receive a liver transplant: Severe alcoholic hepatitis as the first episode of liver decom­pensation *vs* alcoholic cirrhotics with ≥ 6 mo of abstinence. Early liver transplant provided excellent short-term survival in both groups. There were similar rates of alcohol relapse in both groups: 23.5% *vs* 29.2%. Although lacking statistical significance, patients transplanted for AH had higher rates of harmful drinking post-transplant compared to the control group (23.5% *vs* 11.5%, *P* = 0.42). The data was particularly concerning given the two out of the four patients with harming drinking patterns died secondary to recurrent alcohol use (alcohol overdose and medication noncompliance with graft failure, respectively)[163].

Although preliminary results may appear promising, ethical issues pertaining to organ shortage, sociocultural concerns about judicious organ allotment, and recividism risk remain[164]. The feasibility of patient selection through strict psychosocial assessment is limited by resources. An addiction psychiatrist experienced in liver transplant may not be readily available in all centers. Liver transplantation for refractory severe acute alcoholic hepatitis should be judiciously employed in highly selected individuals who are at low risk of recidivism[165].

New therapeutic options for alcoholic hepatitis are needed. Corticosteroid use are helpful in 50% of cases, however they are associated with a higher rate of infections and do not offer long term survival benefit. Treatments targeting gut dysbiosis, innate immunity, inflammation pathways, and apoptosis are currently being studied (Table 1).

**NEW THERAPEUTIC OPTIONS**

***Gut microbiota modification: Probiotics***

Animal studies mimicking alcoholic hepatitis have observed changes in microbial translocation and dysbiosis[166]. Patients with alcoholic hepatitis have abnormalities in bacterial overgrowth, intestinal mucosal damage, increased gut permeability with bacterial translocation, and resulting endotoxemia[167]. The use of probiotics to modify gut bacteria are studied for the treatment of alcoholic hepatitis. Animals studies by Wang *et al*[168]concludes *Lactobacillus* rhamnosus treatment reduced alcohol-induced hepatic inflammation by attenuation of TNF-α production *via* inhibition of TLR-4 and TLR-5 mediated endotoxin activation. A pilot study with mild alcoholic hepatitis patients who received *Bifidobacterium bifidum* and *Lactobacillus plantarum 8PA3* for five days shows significantly reduced ALT, AST, lactate dehydrogenase, total bilirubin, and restoration of gut flora compared to placebo. Other studies have showed that alcoholic cirrhotics have cytokine reduction with reduced liver disease severity and hospitalization when treated with probiotic VSL#3[169,170]*.* Rifaximin is studied for the role of bacterial overgrowth in decompensated alcoholic cirrhotics. Rifamixin administered for 28 d decreased endotoxemia in the systemic and splenic circulation with reduction in portal hypertension. Currently, there are clinical trials examining the role of Lactobacillus rhamnosus, rifaximin, fecal microbiota transplantation, and antibiotics in AH patients[99]*.*

***Immune modulators***

Chronic ethanol stimulation increases the production of inflammatory cytokines and chemokines to induce liver injury. Multiple mechanisms are proposed to modulate the innate immune system. It is not clear if animal and cellular models can be extrapolated for use in humans. Based on animal studies, IL-22 is a hepatoprotective cytokine. Chronic-binge ethanol fed mice treated with recombinant IL-22 protein induced activation of hepatic STAT3 to prevent alcohol-induced steatosis, liver injury, and oxidative stress in a study by Ki *et al*[12]. IL-22 down regulates the expression of fatty acid transport protein. It is found to have antioxidant, apoptotic, proliferative, and antimicrobial properties with minimal side effects[11]. IL-17 levels produced by TH17 cells are elevated in patients with alcoholic hepatitis. IL-17 induces neutrophil recruitment and stimulates hepatic stellate cells to secrete chemokines, such as IL-8 and CXCL[171,172]. Alcoholic hepatitis patients with expression of these chemokines in the liver are correlated with worsening severity of portal hypertension and patient survival[173,174]. Therapeutic agents targeting the reduction of CXCL and IL-17 with IL-22 upregulation can be a new treatment strategy[54,175].

***Liver regeneration: Granulocyte colony-stimulating factor***

Bone marrow-derived stem cells can populate the liver and differentiate into hepatic cells when faced with liver insult. Experimental studies show that granulocyte colony-stimulating factor (G-CSF) promote the mobilization of bone marrow stem cells to ameliorate liver injury and enhance the proliferative capacity of hepatocytes[176]. G-CSF mobilizes CD 34+ cells, increases hepatocyte growth factor, and induces proliferation of hepatic progenitor cells within 7 d of administration in patients with alcoholic cirrhosis with biopsy proven alcoholic steatohepatitis[177]. In a pilot study, 46 patients with severe alcoholic hepatitis were randomized to receive G-CSF ≥ 5 g/kg for 5 d with standard medical therapy (pentoxifylline with nutrition) *vs* standard medical therapy alone. Findings shows a statistically significant number of peripheral CD 34+ cells and improvement of Child Pugh score, MELD, and discriminant function for up to 3 mo in the G-CSF group. Ninety day survival benefit is seen in G-CSF group compared to placebo[178]. The addition of corticosteroids would be helpful in delineating the survival benefit. A clinical trial testing the efficacy of G-CSF in the management of patients with severe alcoholic hepatitis whom have failed corticosteroids is needed.

***FXR/obeticholic acid***

FXRs are nuclear hormone re­ceptors that participate in bilirubin metabolism. Bile acids are the physiologic ligands of FXRs, which regulate bile acid, carbohydrate, and lipid metabolism. In addition, they modulate liver regeneration after injury. FXR activation is protective against cholestatic and fatty liver injury. In a murine model, mice were fed an ethanol or control diet. FXR impairment is exhibited in the ethanol group. FXR agonist therapy is found to be hepatoprotective, likely from suppression of microsomal CYP2E1 enzyme upregulation[179]. FXR activation is shown in other studies to prevent and improve liver fibrosis in mice[180,181].

Obeticholic acid is a selective FXR. A phase 2 clinical trials shows obeticholic acid improved insulin sensitivity and markers of liver inflammation in patients with diabetes and nonalcoholic fatty liver disease. Phase 2 clinical trials are exploring obeticholic acid in patients with alcoholic hepatitis.

***Caspase inhibitors***

Alcohol exposure causes hepatocytes to release ex­tracellular vesicles in a caspase-dependent manner to elicit apoptosis and macrophage activation[182]. Apoptosis may trigger abnormal liver tissue repair, inflammation, regeneration, and fibrosis[183]. Caspase inhibitors may decrease apoptosis and inflammation in a variety of liver diseases. Emricasan is a pan-capsase inhibitor studied in patients with hepatitis C and NASH. In clinical trials, emricasan significantly reduces the aminotransferase activity in non-cirrhotic hepatitis C patients. Similar trends are observed in patients with NASH and hepatitis B, however statistical analysis was not performed on these groups[184]. In NASH studies, mice fed a high fat diet demonstrates a five-fold increase in hepatic apoptosis and 1.5-fold and 1.3-fold increase in caspase-3 and -8, respectively. Mice with emricasan administration demonstrates a reduction in inflammation and fibrosis compared to placebo. Based on the positive preliminary data found in murine NASH models, clinical trials evaluat­ing emricasan for benefit in patients with alcoholic liver disease are ongoing. Thus far, a phase 2 clinical trial concluded that Child Pugh A and B cirrhotic patients with baseline MELD ≥ 15 who are treated with emricasan showed significant improvement compared to placebo in MELD scores, Child-Pugh scores, bilirubin levels, and INR in preliminary data[185].

***Combination therapy: Anakinra-blocks IL-1 beta receptor, pentoxifylline and zinc vs methylprednisolone***

Alcohol-induced liver injury activates Kupffer cells, which stimulation production of inflammasomes and IL-1, which initiate the inflammatory cascade. Effects include liver inflammation, steatosis, injury, and fibrogenesis. Pharmacological inhibition of IL-1 signaling has a hepatoprotective effect. There was recovery from acute-on-chronic alcoholic liver injury[186]. Anakinra, an IL-1 receptor antagonist combined with pentoxifylline and zinc is being studied in phase 2 and 3 clinical trials to examined the efficacy against corticosteroids.

***S-adenosil-L-methionine***

S-adenosil-L-methionine (SAMe) is a direct precursor of glutathione, which serves as a major physiologic defense mechanism against oxidative stress. A recent pilot study randomized two groups of twenty patients each with severe alcoholic hepatitis treated with prednisolone 40 mg daily *vs* prednisolone 40 mg with intravenous SAMe 800 mg for 28 d. After the first week, intravenous SAMe regimen was converted to oral doses of 1200 mg/d for two months. The response rate measured by the Lille’s score is significantly improved in the prednisolone and SAMe (95% of patients) compared to the prednisolone only group (65%). Hepatorenal syndrome occurred in 20% patients in the prednisolone group, but none in the combination treatment group. Difference between the groups regarding 28-d mortality could not be inferred. Although not statistically significant, the six-month survival rate is 90% in the prednisolone plus SAMe group *vs* 75% in the prednisolone group. Larger trials are needed to validate the study results[187].

***Metadoxine***

Metadoxine is an antioxidant, which aids in gluthathione metabolism and inhibits hepatic steatosis[188].The addition of metadoxine with corticosteroids is found to improve 30 and 90 d survival rates. The metadoxine and corticosteroid group is found to have a better treat­ment response based on Lille’s score, lower rates of hepatorenal syndrome, and decreased development and/or progression of hepatic encephalopathy compared to the corticosteroid group. There are no significant adverse side effects[189]. Another study combined metadoxine with either prednisone or pentoxifylline for 30 d. The group receiving metadoxine combined with prednisolone or pentoxifylline had increased three and six-month survival rate of 50% compared to the 20% survival rate in the prednisolone or prednisone only group. The rates of hepatorenal syndrome and hepatic encephalopathy development are significantly less in the metadoxine group, however infections are not[190]. Additional studies with a greater sample size are needed to increase the power of future studies.

***ELAD***

There are ongoing Phase 3 clinical trials of ELAD for acute severe alcoholic hepatitis[191]. Patients with acute renal failure, severe coagulopathy, and MELD > 28 have worse outcomes with ELAD. There are no survival differences between the ELAD over the control group in day 28 and 91. Pre-specified exploratory analysis of 101 patients < age 47 showed an improved 3-mo survival in the ELAD group compared to the control group (81.4% *vs* 67.2%). When analyzed for patients less than 50 years old, creat­inine < 1.3 mg/dL, bilirubin ≥ 16 mg/dL, and INR ≤ 2.5, the 3-mo survival rate was 94% in the ELAD group and 68% in the control group. The most recent ELAD trial, VTL-308 incorporates the new inclusion and exclusion criteria[192]. The preliminary results are eagerly awaited. There are limitations to the use of ELAD, including high cost and stringent inclusion criteria. Patients are usually monitored in the intensive care use with frequent monitoring and blood draws. Currently, there are limited centers performing ELAD research and the patient selection criteria excludes: Alcohol use > 6 wk, persons > 50 years old, severe coagulopathy, and advanced renal failure.

Many therapies have been studied for alcoholic hepatitis without proven efficacy. Treatment with antioxidants, including vitamin E and silymarin do not have a survival benefit in alcoholic hepatitis or cirrhosis patients. Colchi­cine, amlodipine, propylthiouracil, anabolic steroids, and insulin and glucagon combinations are not effective in patients with alcoholic hepatitis[45].

**FUTURE RESEARCH**

Most of the understanding of alcoholic liver disease pathogenesis stem from animal models of alcoholic liver disease recreated *via* ad libitum or intragastric ethanol feeding. Recent publications propose a new model of ad libitum feeding with 40% intake of caloric intake from a Western diet high in cholesterol and saturated fat combined with 60% ethanol *via* intragastric infusion to simulate a “true” model of alcohol hepatitis, where contributing factors such as obesity and alcohol abuse are taken into account. This model recreates findings seen in chronic alcoholic liver disease with superimposed alcoholic hepatitis when a weekly binge dose of ethanol is added. However, the model could not emulate the acute-on-chronic hepatic decompensation seen in alcoholic hepatitis[193,194]. The search for molecular targets through genomic studies holds the future direction of answering unsolved questions about alcoholic hepatitis pathogenesis. Further study of IL-22’s antioxidant, anti-apoptotic, anti-steatosis, antibacterial, proliferative effect, and other hepatoprotective properties in conjunction with the inflammatory and immunomodulatory function of corticosteroids is underway[12,195]. Recent literature highlights the use of biospecimens (*i.e*., liver tissue, peripheral serum, stool) for *in vitro* and *in vivo* studies as a new approach to finding targets for therapy[194]. New findings eludicated under such methods, include impaired bacterial killing from monocyte oxide burst dysfunction and defective T cell function in AH subjects. Although the reversal of defective monocyte oxidative burst is not restored by the IFN-gamma, the negative regulator of Janus Kinase responsible for suppressing cytokine signalling-1 was discovered to have increased expression[46]. Restoration of T-cell interferon gamma production, reduction in production of IL-10 producing T cells, and improvement in neutrophil antibacterial function occurs when antibodies against PD1 and TIM3 are blocked[47].

**CONCLUSION**

Alcoholic hepatitis is increasingly recognized as a form of acute-on-chronic liver failure in patients with underlying alcohol-related disease[196,197]. Patients with severe alcoholic hepatitis remain a challenging population to treat. New treatment options for AH involving gut microbiota modification, immune modulation, promotion of liver regeneration, apoptosis inhibitors, farnesoid receptors, and ELAD appear promising thus far, however the research is still in the preliminary phases. Currently, early liver transplantation for severe AH failing standard medical therapy is not universally implemented and further investigation is warranted. Solving the com­plex pathophysiology of alcoholic hepatitis through transla­tional studies with clinical application is challenging. The study of new animal model simulating “true” AH and use of genomic analysis to provide molecular targets are emerging into present day practice. The utilization of clinical trials fuelled by constant evolving concepts discovered *via* translational research will help determine the endpoints and safety of the new therapeutic options to bridge the gap of a disease with high morbidity and mortality.

**REFERENCES**

1 **Mandayam S**, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. *Semin Liver Dis* 2004; **24**: 217-232 [PMID: 15349801 DOI: 10.1055/s-2004-832936]

2 **Becker U**, Deis A, Sørensen TI, Grønbaek M, Borch-Johnsen K, Müller CF, Schnohr P, Jensen G. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. *Hepatology* 1996; **23**: 1025-1029 [PMID: 8621128 DOI: 10.1002/hep.510230513]

3 **Barrio E**, Tomé S, Rodríguez I, Gude F, Sánchez-Leira J, Pérez-Becerra E, González-Quintela A. Liver disease in heavy drinkers with and without alcohol withdrawal syndrome. *Alcohol Clin Exp Res* 2004; **28**: 131-136 [PMID: 14745311 DOI: 10.1097/01.ALC.0000106301.39746.EB]

4 **Naveau S**, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. *Hepatology* 1997; **25**: 108-111 [PMID: 8985274 DOI: 10.1002/hep.510250120]

5 **O’Shea RS**, Dasarathy S, McCullough AJ. Alcoholic liver disease. *Am J Gastroenterol* 2010; **105**: 14-32; quiz 33 [PMID: 19904248 DOI: 10.1038/ajg.2009.593]

6 **Lucey MR**, Mathurin P, Morgan TR. Alcoholic hepatitis. *N Engl J Med* 2009; **360**: 2758-2769 [PMID: 19553649 DOI: 10.1056/NEJMra0805786]

7 **Crabb DW**, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, McClain C, McCullough A, Mitchell MC, Morgan TR, Nagy L, Radaeva S, Sanyal A, Shah V, Szabo G. Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. *Gastroenterology* 2016; **150**: 785-790 [PMID: 26921783 DOI: 10.1053/j.gastro.2016.02.042]

8 **Li TK**. Quantifying the risk for alcohol-use and alcohol-attribu­table health disorders: present findings and future research needs. *J Gastroenterol Hepatol* 2008; **23** Suppl 1: S2-S8 [PMID: 18336658 DOI: 10.1111/j.1440-1746.2007.05298.x]

9 **Bellentani S**, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Saveria Crocè L, Sasso F, Pozzato G, Cristianini G, Brandi G. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. *Gut* 1997; **41**: 845-850 [PMID: 9462221 DOI: 10.1136/gut.41.6.845]

10 **Zakhari S**, Li TK. Determinants of alcohol use and abuse: Impact of quantity and frequency patterns on liver disease. *Hepatology* 2007; **46**: 2032-2039 [PMID: 18046720 DOI: 10.1002/hep.22010]

11 **Hatton J**, Burton A, Nash H, Munn E, Burgoyne L, Sheron N. Drinking patterns, dependency and life-time drinking history in alcohol-related liver disease. *Addiction* 2009; **104**: 587-592 [PMID: 19215600 DOI: 10.1111/j.1360-0443.2008.02493.x]

12 **Ki SH**, Park O, Zheng M, Morales-Ibanez O, Kolls JK, Bataller R, Gao B. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. *Hepatology* 2010; **52**: 1291-1300 [PMID: 20842630 DOI: 10.1002/hep.23837]

13 **Sandahl TD**, Jepsen P, Thomsen KL, Vilstrup H. Incidence and mortality of alcoholic hepatitis in Denmark 1999-2008: a nationwide population based cohort study. *J Hepatol* 2011; **54**: 760-764 [PMID: 21126790 DOI: 10.1016/j.jhep.2010.07.016]

14 **Jinjuvadia R**, Liangpunsakul S. Trends in Alcoholic Hepatitis-related Hospitalizations, Financial Burden, and Mortality in the United States. *J Clin Gastroenterol* 2015; **49**: 506-511 [PMID: 25198164 DOI: 10.1097/MCG.0000000000000161]

15 **French SW**, Morimoto K TH. Animal models of alcohol-associated liver injury. Alcoholic Liver Disease, Pathology and Pathogenesis. London: Hodder Headline, 1995

16 **Lieber CS**. Metabolism of alcohol. *Clin Liver Dis* 2005; **9**: 1-35 [PMID: 15763227 DOI: 10.1016/j.cld.2004.10.005]

17 **Berg JM**, Tymoczko JL. Section 30.5, Ethanol Alters Energy Metabolism in the Liver. In: Freeman W. Biochemistry. New York, 2002

18 **You M**, Crabb DW. Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver. *Am J Physiol Gastrointest Liver Physiol* 2004; **287**: G1-G6 [PMID: 15194557 DOI: 10.1152/ajpgi.00056.2004]

19 **Reed WD**, Clinkenbeard D, Lane MD. Molecular and catalytic properties of mitochondrial (ketogenic) 3-hydroxy-3-methylglutaryl coenzyme A synthase of liver. *J Biol Chem* 1975; **250**: 3117-3123 [PMID: 804485]

20 **Fischer M**, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. *J Biol Chem* 2003; **278**: 27997-28004 [PMID: 12791698 DOI: 10.1074/jbc.M302140200]

21 **You M**, Matsumoto M, Pacold CM, Cho WK, Crabb DW. The role of AMP-activated protein kinase in the action of ethanol in the liver. *Gastroenterology* 2004; **127**: 1798-1808 [PMID: 15578517]

22 **Ji C**, Chan C, Kaplowitz N. Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model. *J Hepatol* 2006; **45**: 717-724 [PMID: 16879892 DOI: 10.1016/j.jhep.2006.05.009]

23 **Friel PN**, Baer JS, Logan BK. Variability of ethanol absorption and breath concentrations during a large-scale alcohol administration study. *Alcohol Clin Exp Res* 1995; **19**: 1055-1060 [PMID: 7485816]

24 **Viitala K**, Makkonen K, Israel Y, Lehtimäki T, Jaakkola O, Koivula T, Blake JE, Niemelä O. Autoimmune responses against oxidant stress and acetaldehyde-derived epitopes in human alcohol consumers. *Alcohol Clin Exp Res* 2000; **24**: 1103-1109 [PMID: 10924016]

25 **Tuma DJ**, Casey CA. Dangerous byproducts of alcohol breakdown--focus on adducts. *Alcohol Res Health* 2003; **27**: 285-290 [PMID: 15540799]

26 **Chayanupatkul M**, Liangpunsakul S. Alcoholic hepatitis: a comprehensive review of pathogenesis and treatment. *World J Gastroenterol* 2014; **20**: 6279-6286 [PMID: 24876748 DOI: 10.3748/wjg.v20.i20.6279]

27 **Luedde T**, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. *Gastroenterology* 2014; **147**: 765-783.e4 [PMID: 25046161 DOI: 10.1053/j.gastro.2014.07.018]

28 **Lieber CS**. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)--a review. *Alcohol Clin Exp Res* 1999; **23**: 991-1007 [PMID: 10397283]

29 **Masalkar PD**, Abhang SA. Oxidative stress and antioxidant status in patients with alcoholic liver disease. *Clin Chim Acta* 2005; **355**: 61-65 [PMID: 15820479 DOI: 10.1016/j.cccn.2004.12.012]

30 **Malhi H**, Kaufman RJ. Endoplasmic reticulum stress in liver disease. *J Hepatol* 2011; **54**: 795-809 [PMID: 21145844 DOI: 10.1016/j.jhep.2010.11.005]

31 **Cooper G**. The Endoplasmic Reticulum. In: The Cell: A Molecular Approach. Sunderland: Sinauer Asssociates, 2000

32 **Ji C**, Deng Q, Kaplowitz N. Role of TNF-alpha in ethanol-induced hyperhomocysteinemia and murine alcoholic liver injury. *Hepatology* 2004; **40**: 442-451 [PMID: 15368449 DOI: 10.1002/hep.20309]

33 **Petrasek J**, Iracheta-Vellve A, Csak T, Satishchandran A, Kodys K, Kurt-Jones EA, Fitzgerald KA, Szabo G. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. *Proc Natl Acad Sci USA* 2013; **110**: 16544-16549 [PMID: 24052526 DOI: 10.1073/pnas.1308331110]

34 **Crabb DW**, Liangpunsakul S. Alcohol and lipid metabolism. *J Gastroenterol Hepatol* 2006; **21** Suppl 3: S56-S60 [PMID: 16958674 DOI: 10.1111/j.1440-1746.2006.04582.x]

35 **Hernández-Gea V**, Hilscher M, Rozenfeld R, Lim MP, Nieto N, Werner S, Devi LA, Friedman SL. Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy. *J Hepatol* 2013; **59**: 98-104 [PMID: 23485523 DOI: 10.1016/j.jhep.2013.02.016]

36 **Yin M**, Bradford BU, Wheeler MD, Uesugi T, Froh M, Goyert SM, Thurman RG. Reduced early alcohol-induced liver injury in CD14-deficient mice. *J Immunol* 2001; **166**: 4737-4742 [PMID: 11254735]

37 **Gao B**, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. *Gastroenterology* 2011; **141**: 1572-1585 [PMID: 21920463 DOI: 10.1053/j.gastro.2011.09.002]

38 **Michelena J**, Altamirano J, Abraldes JG, Affò S, Morales-Ibanez O, Sancho-Bru P, Dominguez M, García-Pagán JC, Fernández J, Arroyo V, Ginès P, Louvet A, Mathurin P, Mehal WZ, Caballería J, Bataller R. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. *Hepatology* 2015; **62**: 762-772 [PMID: 25761863 DOI: 10.1002/hep.27779]

39 **Bautista AP**. Impact of alcohol on the ability of Kupffer cells to produce chemokines and its role in alcoholic liver disease. *J Gastroenterol Hepatol* 2000; **15**: 349-356 [PMID: 10824877]

40 **Louvet A**, Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment. *Nat Rev Gastroenterol Hepatol* 2015; **12**: 231-242 [PMID: 25782093 DOI: 10.1038/nrgastro.2015.35]

41 **Blackmore LJ**, Ryan JM, Huang X, Hussain M, Triantafyllou E, Vergis N, Vijay GM, Antoniades CG, Thursz MR, Jassem W, Vergani D, Shawcross DL, Ma Y. Acute alcoholic hepatitis and cellular Th1 immune responses to alcohol dehydrogenase. *Lancet* 2015; **385** Suppl 1: S22 [PMID: 26312844 DOI: 10.1016/S0140-6736(15)60337-3]

42 **Laso FJ**, Lapeña P, Madruga JI, San Miguel JF, Orfao A, Iglesias MC, Alvarez-Mon M. Alterations in tumor necrosis factor-alpha, interferon-gamma, and interleukin-6 production by natural killer cell-enriched peripheral blood mononuclear cells in chronic alcoholism: relationship with liver disease and ethanol intake. *Alcohol Clin Exp Res* 1997; **21**: 1226-1231 [PMID: 9347083]

43 **Mandrekar P**, Ambade A, Lim A, Szabo G, Catalano D. An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. *Hepatology* 2011; **54**: 2185-2197 [PMID: 21826694 DOI: 10.1002/hep.24599]

44 **Sheron N**, Bird G, Koskinas J, Portmann B, Ceska M, Lindley I, Williams R. Circulating and tissue levels of the neutrophil chemotaxin interleukin-8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration. *Hepatology* 1993; **18**: 41-46 [PMID: 8325620]

45 **Taïeb J**, Delarche C, Paradis V, Mathurin P, Grenier A, Crestani B, Dehoux M, Thabut D, Gougerot-Pocidalo MA, Poynard T, Chollet-Martin S. Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis. *J Hepatol* 2002; **36**: 342-348 [PMID: 11867177]

46 **Vergis N**, Khamri W, Beale K, Sadiq F, Aletrari MO, Moore C, Atkinson SR, Bernsmeier C, Possamai LA, Petts G, Ryan JM, Abeles RD, James S, Foxton M, Hogan B, Foster GR, O’Brien AJ, Ma Y, Shawcross DL, Wendon JA, Antoniades CG, Thursz MR. Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase. *Gut* 2017; **66**: 519-529 [PMID: 26860769 DOI: 10.1136/gutjnl-2015-310378]

47 **Markwick LJ**, Riva A, Ryan JM, Cooksley H, Palma E, Tranah TH, Manakkat Vijay GK, Vergis N, Thursz M, Evans A, Wright G, Tarff S, O’Grady J, Williams R, Shawcross DL, Chokshi S. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. *Gastroenterology* 2015; **148**: 590-602.e10 [PMID: 25479137 DOI: 10.1053/j.gastro.2014.11.041]

48 **Ceni E**, Mello T, Galli A. Pathogenesis of alcoholic liver disease: role of oxidative metabolism. *World J Gastroenterol* 2014; **20**: 17756-17772 [PMID: 25548474 DOI: 10.3748/wjg.v20.i47.17756]

49 **Frenzer A**, Butler WJ, Norton ID, Wilson JS, Apte MV, Pirola RC, Ryan P, Roberts-Thomson IC. Polymorphism in alcohol-meta­bolizing enzymes, glutathione S-transferases and apolipoprotein E and susceptibility to alcohol-induced cirrhosis and chronic pancreatitis. *J Gastroenterol Hepatol* 2002; **17**: 177-182 [PMID: 11966948]

50 **Monzoni A**, Masutti F, Saccoccio G, Bellentani S, Tiribelli C, Giacca M. Genetic determinants of ethanol-induced liver damage. *Mol Med* 2001; **7**: 255-262 [PMID: 11471570]

51 **Frezza M**, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. *N Engl J Med* 1990; **322**: 95-99 [PMID: 2248624 DOI: 10.1056/NEJM199001113220205]

52 **Shibuya A**, Yoshida A. Genotypes of alcohol-metabolizing enzymes in Japanese with alcohol liver diseases: a strong association of the usual Caucasian-type aldehyde dehydrogenase gene (ALDH1(2)) with the disease. *Am J Hum Genet* 1988; **43**: 744-748 [PMID: 3189338]

53 **Sato N**, Lindros KO, Baraona E, Ikejima K, Mezey E, Järveläinen HA, Ramchandani VA. Sex difference in alcohol-related organ injury. *Alcohol Clin Exp Res* 2001; **25**: 40S-45S [PMID: 11391047]

54 **Zintzaras E**, Stefanidis I, Santos M, Vidal F. Do alcohol-meta­bolizing enzyme gene polymorphisms increase the risk of alcoho­lism and alcoholic liver disease? *Hepatology* 2006; **43**: 352-361 [PMID: 16440362 DOI: 10.1002/hep.21023]

55 **Arsene D**, Farooq O, Bataller R. New therapeutic targets in alcoholic hepatitis. *Hepatol Int* 2016; **10**: 538-552 [PMID: 27072540 DOI: 10.1007/s12072-015-9701-6]

56 **Chamorro AJ**, Torres JL, Mirón-Canelo JA, González-Sarmiento R, Laso FJ, Marcos M. Systematic review with meta-analysis: the I148M variant of patatin-like phospholipase domain-containing 3 gene (PNPLA3) is significantly associated with alcoholic liver cirrhosis. *Aliment Pharmacol Ther* 2014; **40**: 571-581 [PMID: 25060292 DOI: 10.1111/apt.12890]

57 **Atkinson S**. GS03 a genome-wide association study identifies PNPLA3 and SLC38A4 as risk loci for alcoholic hepatitis. *J Hepatol* 2015; **64**: S134 [DOI: 10.1016/S0168-8278(16)01634-2]

58 **Chalasani NP**, Shah V, Sanyal AJ, Liangpunsakal S, Tang Q, Comerford M, Puri P, Radaeva S, Katz BCD. Acute Alcoholic Hepatitis in the United States: Clinical Characteristics, Outcomes and Relationship with PNPLA3 Genotype and Coffee Drinking. In: American College of Gastroenterology Annual Scientific Meeting. Las Vegas, 2016

59 **Diehl AM**. Obesity and alcoholic liver disease. *Alcohol* 2004; **34**: 81-87 [PMID: 15670669 DOI: 10.1016/j.alcohol.2004.07.010]

60 **Trembling PM**, Apostolidou S, Parkes J, Ryan A, Gentry-Maharaj A, Tanwar S, Menon U, Rosenberg WM. Influence of bmi and alcohol on liver-related morbidity and mortality in a cohort of 108,000 women from the general population from UKCTOCS. *J Hepatol* 2013; **58**: S51-52 [DOI: 10.1016/S0168-8278(13)60117-8]

61 **Corrao G**, Aricò S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. *Hepatology* 1998; **27**: 914-919 [PMID: 9537428 DOI: 10.1002/hep.510270404]

62 **Fletcher LM**, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. *Gastroenterology* 2002; **122**: 281-289 [PMID: 11832443]

63 **Novo-Veleiro I**, Alvela-Suárez L, Chamorro AJ, González-Sarmiento R, Laso FJ, Marcos M. Alcoholic liver disease and hepatitis C virus infection. *World J Gastroenterol* 2016; **22**: 1411-1420 [PMID: 26819510 DOI: 10.3748/wjg.v22.i4.1411]

64 **Armstrong GL**, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. *Ann Intern Med* 2006; **144**: 705-714 [PMID: 16702586]

65 **Tsui JI**, Pletcher MJ, Vittinghoff E, Seal K, Gonzales R. Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems. *J Hepatol* 2006; **44**: 262-266 [PMID: 16226823 DOI: 10.1016/j.jhep.2005.07.027]

66 **Chen CM**, Yoon YH, Yi HY, Lucas DL. Alcohol and hepatitis C mortality among males and females in the United States: a life table analysis. *Alcohol Clin Exp Res* 2007; **31**: 285-292 [PMID: 17250621 DOI: 10.1111/j.1530-0277.2006.00304.x]

67 **Cromie SL**, Jenkins PJ, Bowden DS, Dudley FJ. Chronic hepatitis C: effect of alcohol on hepatitic activity and viral titre. *J Hepatol* 1996; **25**: 821-826 [PMID: 9007708]

68 **Wiley TE**, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. *Hepatology* 1998; **28**: 805-809 [PMID: 9731576 DOI: 10.1002/hep.510280330]

69 **Larkin J**, Clayton MM, Liu J, Feitelson MA. Chronic ethanol consumption stimulates hepatitis B virus gene expression and replication in transgenic mice. *Hepatology* 2001; **34**: 792-797 [PMID: 11584377 DOI: 10.1053/jhep.2001.27565]

70 **Khan KN**, Yatsuhashi H. Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients. *Alcohol Alcohol* 2016; **35**: 286-295 [PMID: 10869250]

71 **Chung WG**, Kim HJ, Choe YG, Seok HS, Chon CW, Cho YK, Kim BI, Koh YY. Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection. *Clin Mol Hepatol* 2012; **18**: 195-202 [PMID: 22893870 DOI: 10.3350/cmh.2012.18.2.195]

72 **Bruggmann P**, Dampz M, Gerlach T, Kravecz L, Falcato L. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. *Drug Alcohol Depend* 2010; **110**: 167-171 [PMID: 20334985 DOI: 10.1016/j.drugalcdep.2010.02.016]

73 **Spradling PR**, Bulkow L, Teshale EH, Negus S, Homan C, Simons B, McMahon BJ. Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection. *J Hepatol* 2014; **61**: 785-791 [PMID: 24911461 DOI: 10.1016/j.jhep.2014.05.045]

74 **Mueller S**, Millonig G, Seitz HK. Alcoholic liver disease and hepatitis C: a frequently underestimated combination. *World J Gastroenterol* 2009; **15**: 3462-3471 [PMID: 19630099 DOI: 10.3748/wjg.15.3462]

75 **Zhao N**, Zhang AS, Enns CA. Iron regulation by hepcidin. *J Clin Invest* 2013; **123**: 2337-2343 [PMID: 23722909 DOI: 10.1172/JCI67225]

76 **Fletcher LM**, Powell LW. Hemochromatosis and alcoholic liver disease. *Alcohol* 2003; **30**: 131-136 [PMID: 12957297]

77 **Ganne-Carrié N**, Christidis C, Chastang C, Ziol M, Chapel F, Imbert-Bismut F, Trinchet JC, Guettier C, Beaugrand M. Liver iron is predictive of death in alcoholic cirrhosis: a multivariate study of 229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis: a prospective follow up study. *Gut* 2000; **46**: 277-282 [PMID: 10644325]

78 **Niederau C**, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. *N Engl J Med* 1985; **313**: 1256-1262 [PMID: 4058506 DOI: 10.1056/NEJM198511143132004]

79 **Mccullough AJ**. The Epidemiology and Risk Factors of NASH [Internet]. In: Fatty Liver Disease. Oxford, UK: Blackwell Publishing Ltd, 2016: 23-37 [DOI: 10.1002/9780470987438.ch3]

80 **Donohue TM**, Cederbaum AI, French SW, Barve S, Gao B, Osna NA. Role of the proteasome in ethanol-induced liver pathology. *Alcohol Clin Exp Res* 2007; **31**: 1446-1459 [PMID: 17760783 DOI: 10.1111/j.1530-0277.2007.00454.x]

81 **Caldwell S**, Ikura Y, Dias D, Isomoto K, Yabu A, Moskaluk C, Pramoonjago P, Simmons W, Scruggs H, Rosenbaum N, Wilkinson T, Toms P, Argo CK, Al-Osaimi AM, Redick JA. Hepatocellular ballooning in NASH. *J Hepatol* 2010; **53**: 719-723 [PMID: 20624660 DOI: 10.1016/j.jhep.2010.04.031]

82 **Alpert L**, Hart J. The Pathology of Alcoholic Liver Disease. *Clin Liver Dis* 2016; **20**: 473-489 [PMID: 27373610 DOI: 10.1016/j.cld.2016.02.006]

83 **Tannapfel A**, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. *Virchows Arch* 2011; **458**: 511-523 [PMID: 21442288 DOI: 10.1007/s00428-011-1066-1]

84 **Dunn W**, Angulo P, Sanderson S, Jamil LH, Stadheim L, Rosen C, Malinchoc M, Kamath PS, Shah VH. Utility of a new model to diagnose an alcohol basis for steatohepatitis. *Gastroenterology* 2006; **131**: 1057-1063 [PMID: 17030176 DOI: 10.1053/j.gastro. 2006.08.020]

85 **Dam-Larsen S**, Becker U, Franzmann MB, Larsen K, Christo­ffersen P, Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. *Scand J Gastroenterol* 2009; **44**: 1236-1243 [PMID: 19670076 DOI: 10.1080/00365520903171284]

86 **Botros M**, Sikaris KA. The de ritis ratio: the test of time. *Clin Biochem Rev* 2013; **34**: 117-130 [PMID: 24353357]

87 **Karsan HA**, Parekh S. Management of alcoholic hepatitis: Current concepts. *World J Hepatol* 2012; **4**: 335-341 [PMID: 23355911 DOI: 10.4254/wjh.v4.i12.335]

88 **Fiellin DA**, O’Connor PG, Holmboe ES, Horwitz RI. Risk for delirium tremens in patients with alcohol withdrawal syndrome. *Subst Abus* 2002; **23**: 83-94 [PMID: 12444353 DOI: 10.1080/08897070209511478]

89 **Hamid R**, Forrest EH. Is histology required for the diagnosis of alcoholic hepatitis? a review of published randomised controlled trials. *Gut* 2011; **60**: A233-A233 [DOI: 10.1136/gut.2011.239301.492]

90 **Singal AK**, Kodali S, Vucovich LA, Darley-Usmar V, Schiano TD. Diagnosis and Treatment of Alcoholic Hepatitis: A Systematic Review. *Alcohol Clin Exp Res* 2016; **40**: 1390-1402 [PMID: 27254289 DOI: 10.1111/acer.13108]

91 **Yeluru A**, Cuthbert JA, Casey L, Mitchell MC. Alcoholic Hepatitis: Risk Factors, Pathogenesis, and Approach to Treatment. *Alcohol Clin Exp Res* 2016; **40**: 246-255 [PMID: 26842243 DOI: 10.1111/acer.12956]

92 **European Association for the Study of Liver**. EASL clinical practical guidelines: management of alcoholic liver disease. *J Hepatol* 2012; **57**: 399-420 [PMID: 22633836 DOI: 10.1016/j.jhep.2012.04.004]

93 **Maddrey WC**, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI. Corticosteroid therapy of alcoholic hepatitis. *Gastro­enterology* 1978; **75**: 193-199 [PMID: 352788]

94 **Sheth M**, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. *BMC Gastroenterol* 2002; **2**: 2 [PMID: 11835693 DOI: 10.1186/1471-230x-2-2]

95 **Srikureja W**, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. *J Hepatol* 2005; **42**: 700-706 [PMID: 15826720 DOI: 10.1016/j.jhep.2004.12.022]

96 **Dunn W**, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, Malinchoc M, Kamath PS, Shah V. MELD accurately predicts mortality in patients with alcoholic hepatitis. *Hepatology* 2005; **41**: 353-358 [PMID: 15660383 DOI: 10.1002/hep.20503]

97 **Louvet A**, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Dharancy S, Texier F, Hollebecque A, Serfaty L, Boleslawski E, Deltenre P, Canva V, Pruvot FR, Mathurin P. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. *Hepatology* 2007; **45**: 1348-1354 [PMID: 17518367 DOI: 10.1002/hep.21607]

98 **Garcia-Saenz-de-Sicilia M**, Duvoor C, Altamirano J, Duarte-Rojo A. Early prediction of response in patients with severe acute alcoholic hepatitis by using Lille model on day 4. Aasld Liver Meeting, 2015

99 **Mathurin P**, O’Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, Ramond MJ, Naveau S, Maddrey WC, Morgan TR. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. *Gut* 2011; **60**: 255-260 [PMID: 20940288 DOI: 10.1136/gut.2010.224097]

100 **Gustot T**, Maillart E, Bocci M, Surin R, Trépo E, Degré D, Lucidi V, Taccone FS, Delforge ML, Vincent JL, Donckier V, Jacobs F, Moreno C. Invasive aspergillosis in patients with severe alcoholic hepatitis. *J Hepatol* 2014; **60**: 267-274 [PMID: 24055548 DOI: 10.1016/j.jhep.2013.09.011]

101 **Forrest EH**, Morris AJ, Stewart S, Phillips M, Oo YH, Fisher NC, Haydon G, O’Grady J, Day CP. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. *Gut* 2007; **56**: 1743-1746 [PMID: 17627961 DOI: 10.1136/gut.2006.099226]

102 **Altamirano J**, Miquel R, Katoonizadeh A, Abraldes JG, Duarte-Rojo A, Louvet A, Augustin S, Mookerjee RP, Michelena J, Smyrk TC, Buob D, Leteurtre E, Rincón D, Ruiz P, García-Pagán JC, Guerrero-Marquez C, Jones PD, Barritt AS, Arroyo V, Bruguera M, Bañares R, Ginès P, Caballería J, Roskams T, Nevens F, Jalan R, Mathurin P, Shah VH, Bataller R. A histologic scoring system for prognosis of patients with alcoholic hepatitis. *Gastroenterology* 2014; **146**: 1231-1239.e1-6 [PMID: 24440674 DOI: 10.1053/j.gastro.2014.01.018]

103 **Altamirano J**, Fagundes C, Dominguez M, García E, Michelena J, Cárdenas A, Guevara M, Pereira G, Torres-Vigil K, Arroyo V, Caballería J, Ginès P, Bataller R. Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. *Clin Gastroenterol Hepatol* 2012; **10**: 65-71.e3 [PMID: 21946124 DOI: 10.1016/j.cgh.2011.09.011]

104 **Altamirano J**, Higuera-de laTijera F, Duarte-Rojo A, Martínez-Vázquez MA, Abraldes JG, Herrera-Jiménez LE, Michelena J, Zapata L, Perez-Hernández J, Torre A, Gonzáles-González JA, Cardenas A, Dominguez M, Arroyo V, Ginès P, Caballería J, Bataller R. The amount of alcohol consumption negatively impacts short-term mortality in Mexican patients with alcoholic hepatitis. *Am J Gastroenterol* 2011; **106**: 1472-1480 [PMID: 21556041 DOI: 10.1038/ajg.2011.141]

105 **Liangpunsakul S**. Clinical characteristics and mortality of hospi­talized alcoholic hepatitis patients in the United States. *J Clin Gastroenterol* 2011; **45**: 714-719 [PMID: 21085006 DOI: 10.1097/MCG.0b013e3181fdef1d]

106 **Poynard T**, Zourabichvili O, Hilpert G, Naveau S, Poitrine A, Benatar C, Chaput JC. Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients. *Hepatology* 2016; **4**: 324-327 [PMID: 6142856]

107 **Shasthry SM**, Sarin SK. New treatment options for alcoholic hepatitis. *World J Gastroenterol* 2016; **22**: 3892-3906 [PMID: 27099434 DOI: 10.3748/wjg.v22.i15.3892]

108 **Rachakonda V**, Gabbert C, Raina A, Bell LN, Cooper S, Malik S, Behari J. Serum metabolomic profiling in acute alcoholic hepatitis identifies multiple dysregulated pathways. *PLoS One* 2014; **9**: e113860 [PMID: 25461442 DOI: 10.1371/journal.pone.0113860]

109 **Rachakonda V**, Gabbert C, Raina A, Li H, Malik S, DeLany JP, Behari J. Stratification of risk of death in severe acute alcoholic hepatitis using a panel of adipokines and cytokines. *Alcohol Clin Exp Res* 2014; **38**: 2712-2721 [PMID: 25421508 DOI: 10.1111/acer.12558]

110 **Hanouneh IA**, Zein NN, Cikach F, Dababneh L, Grove D, Alkhouri N, Lopez R, Dweik RA. The breathprints in patients with liver disease identify novel breath biomarkers in alcoholic hepatitis. *Clin Gastroenterol Hepatol* 2014; **12**: 516-523 [PMID: 24036050 DOI: 10.1016/j.cgh.2013.08.048]

111 **Kumar K**, Mohindra S, Raj M, Choudhuri G. Procalcitonin as a marker of sepsis in alcoholic hepatitis. *Hepatol Int* 2014; **8**: 436-442 [PMID: 26202645 DOI: 10.1007/s12072-014-9540-x]

112 **Lanthier N**, Rubbia-Brandt L, Lin-Marq N, Clément S, Frossard JL, Goossens N, Hadengue A, Spahr L. Hepatic cell proliferation plays a pivotal role in the prognosis of alcoholic hepatitis. *J Hepatol* 2015; **63**: 609-621 [PMID: 25872168 DOI: 10.1016/j.jhep.2015.04.003]

113 **Spahr L**, Rubbia-Brandt L, Frossard JL, Giostra E, Rougemont AL, Pugin J, Fischer M, Egger H, Hadengue A. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. *J Hepatol* 2002; **37**: 448-455 [PMID: 12217597]

114 **Blaya D**, Coll M, Rodrigo-Torres D, Vila-Casadesús M, Altamirano J, Llopis M, Graupera I, Perea L, Aguilar-Bravo B, Díaz A, Banales JM, Clària J, Lozano JJ, Bataller R, Caballería J, Ginès P, Sancho-Bru P. Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. *Gut* 2016; **65**: 1535-1545 [PMID: 27196584 DOI: 10.1136/gutjnl-2015-311314]

115 **Kronenberger B**, Rudloff I, Bachmann M, Brunner F, Kapper L, Filmann N, Waidmann O, Herrmann E, Pfeilschifter J, Zeuzem S, Piiper A, Mühl H. Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study. *BMC Med* 2012; **10**: 102 [PMID: 22967278 DOI: 10.1186/1741-7015-10-102]

116 **Pessione F**, Ramond MJ, Peters L, Pham BN, Batel P, Rueff B, Valla DC. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. *Liver Int* 2003; **23**: 45-53 [PMID: 12640727]

117 **Veldt BJ**, Lainé F, Guillygomarc’h A, Lauvin L, Boudjema K, Messner M, Brissot P, Deugnier Y, Moirand R. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. *J Hepatol* 2002; **36**: 93-98 [PMID: 11804670]

118 **Powell WJ**, Klatskin G. Duration of survival in patients with Laennec’s cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. *Am J Med* 1968; **44**: 406-420 [PMID: 5641303]

119 **Alexander JF**, Lischner MW, Galambos JT. Natural history of alcoholic hepatitis. II. The long-term prognosis. *Am J Gastroenterol* 1971; **56**: 515-525 [PMID: 5134879]

120 **Khan A**, Tansel A, White DL, Kayani WT, Bano S, Lindsay J, El-Serag HB, Kanwal F. Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver Disease: A Systematic Review. *Clin Gastroenterol Hepatol* 2016; **14**: 191-202.e1-4; quiz e20 [PMID: 26256464 DOI: 10.1016/j.cgh.2015.07.047]

121 **Miller WR**, Walters ST, Bennett ME. How effective is alcoholism treatment in the United States? *J Stud Alcohol* 2001; **62**: 211-220 [PMID: 11327187]

122 **Edwards S**, Kenna GA, Swift RM, Leggio L. Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review. *Curr Pharm Des* 2011; **17**: 1323-1332 [PMID: 21524263]

123 **Center for Substance Abuse Treatment**. Incorporating Alcohol Pharmacotherapies Into Medical Practice: A Review of the Literature [Internet]. Substance Abuse and Mental Health Services Administration (US); 2009 [PMID: 22514856]

124 **West S**, Garbutt J, Carey TS, Lux LJ, Jackman AM, Tolleson-Rinehart S, Lohr KN, Crews FT. Pharmacotherapy for Alcohol Dependence: Summary [Internet]. In: AHRQ Evidence Report Summaries. Rockville: Agency for Healthcare Research and Quality (US), 1999. [cited 2016 Oct 20]. Available from: URL: https://www.ncbi.nlm.nih.gov/books/NBK11857/

125 **Vanjak D**, Samuel D, Gosset F, Derrida S, Moreau R, Soupison T, Soulier A, Bismuth H, Sicot C. [Fulminant hepatitis induced by disulfiram in a patient with alcoholic cirrhosis. Survival after liver transplantation]. *Gastroenterol Clin Biol* 1989; **13**: 1075-1078 [PMID: 2625187]

126 **Volpicelli JR**, Clay KL, Watson NT, O’Brien CP. Naltrexone in the treatment of alcoholism: predicting response to naltrexone. *J Clin Psychiatry* 1995; **56** Suppl 7: 39-44 [PMID: 7673104]

127 **Liang R**, Liu A, Perumpail RB, Wong RJ, Ahmed A. Advances in alcoholic liver disease: An update on alcoholic hepatitis. *World J Gastroenterol* 2015; **21**: 11893-11903 [PMID: 26576078 DOI: 10.3748/wjg.v21.i42.11893]

128 **Mason BJ**. Acamprosate in the treatment of alcohol dependence. *Expert Opin Pharmacother* 2005; **6**: 2103-2115 [PMID: 16197362 DOI: 10.1517/14656566.6.12.2103]

129 **Berger L**, Fisher M, Brondino M, Bohn M, Gwyther R, Longo L, Beier N, Ford A, Greco J, Garbutt JC. Efficacy of acamprosate for alcohol dependence in a family medicine setting in the United States: a randomized, double-blind, placebo-controlled study. *Alcohol Clin Exp Res* 2013; **37**: 668-674 [PMID: 23134193 DOI: 10.1111/acer.12010]

130 **Mann K**, Lemenager T, Hoffmann S, Reinhard I, Hermann D, Batra A, Berner M, Wodarz N, Heinz A, Smolka MN, Zimmermann US, Wellek S, Kiefer F, Anton RF. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. *Addict Biol* 2013; **18**: 937-946 [PMID: 23231446 DOI: 10.1111/adb.12012]

131 **Addolorato G**, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D’Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. *Lancet* 2007; **370**: 1915-1922 [PMID: 18068515 DOI: 10.1016/S0140-6736(07)61814-5]

132 **Caputo F**, Bernardi M, Zoli G. Efficacy and safety of γ-hydro­xybutyrate in treating alcohol withdrawal syndrome in an alcohol-dependent inpatient with decompensated liver cirrhosis: a case report. *J Clin Psychopharmacol* 2011; **31**: 140-141 [PMID: 21192167 DOI: 10.1097/JCP.0b013e318203b36f]

133 **Mendenhall CL**, Tosch T, Weesner RE, Garcia-Pont P, Goldberg SJ, Kiernan T, Seeff LB, Sorell M, Tamburro C, Zetterman R. VA cooperative study on alcoholic hepatitis. II: Prognostic significance of protein-calorie malnutrition. *Am J Clin Nutr* 1986; **43**: 213-218 [PMID: 3080866]

134 **Mezey E**. Interaction between alcohol and nutrition in the patho­genesis of alcoholic liver disease. *Semin Liver Dis* 1991; **11**: 340-348 [PMID: 1763339 DOI: 10.1055/s-2008-1040451]

135 **Mendenhall CL**, Anderson S, Weesner RE, Goldberg SJ, Crolic KA. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. *Am J Med* 1984; **76**: 211-222 [PMID: 6421159]

136 **O’Shea RS**, Dasarathy S, McCullough AJ. Alcoholic liver disease. *Hepatology* 2010; **51**: 307-328 [PMID: 20034030 DOI: 10.1002/hep.23258]

137 **Moreno C**, Deltenre P, Senterre C, Louvet A, Gustot T, Bastens B, Hittelet A, Piquet MA, Laleman W, Orlent H, Lasser L, Sersté T, Starkel P, De Koninck X, Negrin Dastis S, Delwaide J, Colle I, de Galocsy C, Francque S, Langlet P, Putzeys V, Reynaert H, Degré D, Trépo E. Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids. *Gastroenterology* 2016; **150**: 903-910.e8 [PMID: 26764182 DOI: 10.1053/j.gastro.2015.12.038]

138 **Puri P**, Thursz M. Intensive Enteral Nutrition in Alcoholic Hepatitis: More Food for Thought. *Gastroenterology* 2016; **150**: 803-805 [PMID: 26924095 DOI: 10.1053/j.gastro.2016.02.061]

139 **Mathurin P**, Mendenhall CL, Carithers RL, Ramond MJ, Maddrey WC, Garstide P, Rueff B, Naveau S, Chaput JC, Poynard T. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. *J Hepatol* 2002; **36**: 480-487 [PMID: 11943418]

140 **Barnes PJ**, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. *N Engl J Med* 1997; **336**: 1066-1071 [PMID: 9091804 DOI: 10.1056/NEJM19970 4103361506]

141 **Spahr L**, Rubbia-Brandt L, Pugin J, Giostra E, Frossard JL, Borisch B, Hadengue A. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. *J Hepatol* 2001; **35**: 582-589 [PMID: 11690703]

142 **Rambaldi A**, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. *Aliment Pharmacol Ther* 2008; **27**: 1167-1178 [PMID: 18363896 DOI: 10.1111/j.1365-2036.2008.03685.x]

143 **Sougioultzis S**, Dalakas E, Hayes PC, Plevris JN. Alcoholic hepatitis: from pathogenesis to treatment. *Curr Med Res Opin* 2005; **21**: 1337-1346 [PMID: 16197651 DOI: 10.1185/0300 79905X56493]

144 **Park SH**, Kim DJ, Kim YS, Yim HJ, Tak WY, Lee HJ, Sohn JH, Yoon KT, Kim IH, Kim HS, Um SH, Baik SK, Lee JS, Suk KT, Kim SG, Suh SJ, Park SY, Kim TY, Jang JY. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial. *J Hepatol* 2014; **61**: 792-798 [PMID: 24845609 DOI: 10.1016/j.jhep.2014.05.014]

145 **De BK**, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. *World J Gastroenterol* 2009; **15**: 1613-1619 [PMID: 19340904 DOI: 10.3748/wjg.15.1613]

146 **Mathurin P**, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, Anty R, Diaz E, Thabut D, Moirand R, Lebrec D, Moreno C, Talbodec N, Paupard T, Naveau S, Silvain C, Pageaux GP, Sobesky R, Canva-Delcambre V, Dharancy S, Salleron J, Dao T. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. *JAMA* 2013; **310**: 1033-1041 [PMID: 24026598 DOI: 10.1001/jama.2013.276300]

147 **Sidhu SS**, Goyal O, Singla P, Gupta D, Sood A, Chhina RS, Soni RK. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). *Dig Dis Sci* 2012; **57**: 1664-1671 [PMID: 22388710 DOI: 10.1007/s10620-012-2097-4]

148 **Thursz MR**, Richardson P, Allison M, Austin A, Bowers M, Day CP, Downs N, Gleeson D, MacGilchrist A, Grant A, Hood S, Masson S, McCune A, Mellor J, O’Grady J, Patch D, Ratcliffe I, Roderick P, Stanton L, Vergis N, Wright M, Ryder S, Forrest EH. Prednisolone or pentoxifylline for alcoholic hepatitis. *N Engl J Med* 2015; **372**: 1619-1628 [PMID: 25901427 DOI: 10.1056/NEJMoa1412278]

149 **Singh S**, Murad MH, Chandar AK, Bongiorno CM, Singal AK, Atkinson SR, Thursz MR, Loomba R, Shah VH. Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis. *Gastroenterology* 2015; **149**: 958-70.e12 [PMID: 26091937 DOI: 10.1053/j.gastro.2015.06.006]

150 **Thursz MR**, Louvet A. Corticosteroids are the only remaining pharmacological option for severe alcoholic hepatitis: a meta-analysis of individual data on 1974 patients [Internet]. Wiley-Blackwell, 2016: 605A-605A. Available from: URL: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER\_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493803010&DestLinkType=FullRecord&DestApp=ALL\_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

151 **Akriviadis E**, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. *Gastroenterology* 2000; **119**: 1637-1648 [PMID: 11113085]

152 **Phillips M**, Curtis H, Portmann B, Donaldson N, Bomford A, O’Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis--a randomised clinical trial. *J Hepatol* 2006; **44**: 784-790 [PMID: 16469404 DOI: 10.1016/j.jhep.2005.11.039]

153 **Nguyen-Khac E**, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B, Dewaele F, Ghrib S, Rudler M, Carbonell N, Tossou H, Bental A, Bernard-Chabert B, Dupas JL. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. *N Engl J Med* 2011; **365**: 1781-1789 [PMID: 22070475 DOI: 10.1056/NEJMoa1101214]

154 **Naveau S**, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broët P, Emilie D. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. *Hepatology* 2004; **39**: 1390-1397 [PMID: 15122768 DOI: 10.1002/hep.20206]

155 **Boetticher NC**, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath PS, Shah VH. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. *Gastroenterology* 2008; **135**: 1953-1960 [PMID: 18848937 DOI: 10.1053/j.gastro.2008.08.057]

156 **Mackie J**, Groves K, Hoyle A, Garcia C, Garcia R, Gunson B, Neuberger J. Orthotopic liver transplantation for alcoholic liver disease: a retrospective analysis of survival, recidivism, and risk factors predisposing to recidivism. *Liver Transpl* 2001; **7**: 418-427 [PMID: 11349262 DOI: 10.1053/jlts.2001.23789]

157 **Beresford TP**, Everson GT. Liver transplantation for alcoholic liver disease: bias, beliefs, 6-month rule, and relapse--but where are the data? *Liver Transpl* 2000; **6**: 777-778 [PMID: 11084067 DOI: 10.1053/jlts.2000.19027]

158 **Bravata DM**, Olkin I, Barnato AE, Keeffe EB, Owens DK. Employment and alcohol use after liver transplantation for alcoholic and nonalcoholic liver disease: a systematic review. *Liver Transpl* 2001; **7**: 191-203 [PMID: 11244159 DOI: 10.1053/jlts.2001.22326]

159 **Donckier V**, Lucidi V, Gustot T, Moreno C. Ethical considerations regarding early liver transplantation in patients with severe alcoholic hepatitis not responding to medical therapy. *J Hepatol* 2014; **60**: 866-871 [PMID: 24291238 DOI: 10.1016/j.jhep.2013.11.015]

160 **Singal AK**, Bashar H, Anand BS, Jampana SC, Singal V, Kuo YF. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database. *Hepatology* 2012; **55**: 1398-1405 [PMID: 22213344 DOI: 10.1002/hep.25544]

161 **Mathurin P**, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, Castel H, Duhamel A, Pageaux GP, Leroy V, Dharancy S, Louvet A, Boleslawski E, Lucidi V, Gustot T, Francoz C, Letoublon C, Castaing D, Belghiti J, Donckier V, Pruvot FR, Duclos-Vallée JC. Early liver transplantation for severe alcoholic hepatitis. *N Engl J Med* 2011; **365**: 1790-1800 [PMID: 22070476 DOI: 10.1056/NEJMoa1105703]

162 **Im GY**, Kim-Schluger L, Shenoy A, Schubert E, Goel A, Friedman SL, Florman S, Schiano TD. Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States--A Single-Center Experience. *Am J Transplant* 2016; **16**: 841-849 [PMID: 26710309 DOI: 10.1111/ajt.13586]

163 **Lee BP**, Chen PH, Haugen C, Hernaez R, Gurakar A, Philosophe B, Dagher N, Moore SA, Li Z, Cameron AM. Three-year Results of a Pilot Program in Early Liver Transplantation for Severe Alcoholic Hepatitis. *Ann Surg* 2017; **265**: 20-29 [PMID: 27280501 DOI: 10.1097/SLA.0000000000001831]

164 **Singal AK**, Kamath PS, Gores GJ, Shah VH. Alcoholic hepatitis: current challenges and future directions. *Clin Gastroenterol Hepatol* 2014; **12**: 555-564; quiz e31-32 [PMID: 23811249 DOI: 10.1016/j.cgh.2013.06.013]

165 **Jesudian AB**, Brown RS. Acute alcoholic hepatitis as indication for liver transplantation. *Curr Opin Organ Transplant* 2016; **21**: 107-110 [PMID: 26867048 DOI: 10.1097/MOT.000000 0000000285]

166 **Yan AW**, Schnabl B. Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease. *World J Hepatol* 2012; **4**: 110-118 [PMID: 22567183 DOI: 10.4254/wjh.v4.i4.110]

167 **McClain C**, Hill D, Schmidt J, Diehl AM. Cytokines and alcoholic liver disease. *Semin Liver Dis* 1993; **13**: 170-182 [PMID: 8337603 DOI: 10.1055/s-2007-1007347]

168 **Wang Y**, Liu Y, Kirpich I, Ma Z, Wang C, Zhang M, Suttles J, McClain C, Feng W. Lactobacillus rhamnosus GG reduces hepatic TNFα production and inflammation in chronic alcohol-induced liver injury. *J Nutr Biochem* 2013; **24**: 1609-1615 [PMID: 23618528 DOI: 10.1016/j.jnutbio.2013.02.001]

169 **Loguercio C**, Federico A, Tuccillo C, Terracciano F, D’Auria MV, De Simone C, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. *J Clin Gastroenterol* 2005; **39**: 540-543 [PMID: 15942443]

170 **Dhiman RK**, Rana B, Agrawal S, Garg A, Chopra M, Thumburu KK, Khattri A, Malhotra S, Duseja A, Chawla YK. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. *Gastroenterology* 2014; **147**: 1327-1337.e3 [PMID: 25450083 DOI: 10.1053/j.gastro. 2014.08.031]

171 **Maltby J**, Wright S, Bird G, Sheron N. Chemokine levels in human liver homogenates: associations between GRO alpha and histopathological evidence of alcoholic hepatitis. *Hepatology* 1996; **24**: 1156-1160 [PMID: 8903391 DOI: 10.1053/jhep.1996.v24.pm0008903391]

172 **Lemmers A**, Moreno C, Gustot T, Maréchal R, Degré D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Le Moine O, Devière J. The interleukin-17 pathway is involved in human alcoholic liver disease. *Hepatology* 2009; **49**: 646-657 [PMID: 19177575 DOI: 10.1002/hep.22680]

173 **Dominguez M**, Miquel R, Colmenero J, Moreno M, García-Pagán JC, Bosch J, Arroyo V, Ginès P, Caballería J, Bataller R. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. *Gastroenterology* 2009; **136**: 1639-1650 [PMID: 19208360 DOI: 10.1053/j.gastro.2009.01.056]

174 **Colmenero J**, Bataller R, Sancho-Bru P, Bellot P, Miquel R, Moreno M, Jares P, Bosch J, Arroyo V, Caballería J, Ginès P. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. *Gastroenterology* 2007; **132**: 687-697 [PMID: 17258719 DOI: 10.1053/j.gastro. 2006.12.036]

175 **Torok NJ**. Update on Alcoholic Hepatitis. *Biomolecules* 2015; **5**: 2978-2986 [PMID: 26540078 DOI: 10.3390/biom5042978]

176 **Theocharis SE**, Papadimitriou LJ, Retsou ZP, Margeli AP, Ninos SS, Papadimitriou JD. Granulocyte-colony stimulating factor administration ameliorates liver regeneration in animal model of fulminant hepatic failure and encephalopathy. *Dig Dis Sci* 2003; **48**: 1797-1803 [PMID: 14561004]

177 **Spahr L**, Lambert JF, Rubbia-Brandt L, Chalandon Y, Frossard JL, Giostra E, Hadengue A. Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. *Hepatology* 2008; **48**: 221-229 [PMID: 18537187 DOI: 10.1002/hep.22317]

178 **Singh V**, Sharma AK, Narasimhan RL, Bhalla A, Sharma N, Sharma R. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. *Am J Gastroenterol* 2014; **109**: 1417-1423 [PMID: 24935272 DOI: 10.1038/ajg.2014.154]

179 **Wu W**, Zhu B, Peng X, Zhou M, Jia D, Gu J. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. *Biochem Biophys Res Commun* 2014; **443**: 68-73 [PMID: 24269813 DOI: 10.1016/j.bbrc.2013.11.057]

180 **Fiorucci S**, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pellicciari R, Morelli A. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. *Gastroenterology* 2004; **127**: 1497-1512 [PMID: 15521018]

181 **Fiorucci S**, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Morelli A, Pruzanski M, Pellicciari R. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. *J Pharmacol Exp Ther* 2005; **315**: 58-68 [PMID: 15980055 DOI: 10.1124/jpet.105.085597]

182 **Verma VK**, Li H, Wang R, Hirsova P, Mushref M, Liu Y, Cao S, Contreras PC, Malhi H, Kamath PS, Gores GJ, Shah VH. Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles. *J Hepatol* 2016; **64**: 651-660 [PMID: 26632633 DOI: 10.1016/j.jhep.2015.11.020]

183 **Ghavami S**, Hashemi M, Kadkhoda K, Alavian SM, Bay GH, Los M. Apoptosis in liver diseases--detection and therapeutic applications. *Med Sci Monit* 2005; **11**: RA337-RA345 [PMID: 16258409]

184 **Pockros PJ**, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. *Hepatology* 2007; **46**: 324-329 [PMID: 17654603 DOI: 10.1002/hep.21664]

185 **Frenette C**, Morelli G, Shiffman M, Frederick RT, Rubin RA, Fallon M, Yamashita M, Spada AP, Chan L, Hagerty DH. Emricasan (IDN-6556) Orally for Three Months in Patients with Cirrhosis and Meld Scores 11–18 Improves Clinical Parameters of Cirrhosis in Patients with Baseline Meld Score ≥ 15. *J Hepatol* 2016; **64**: S210 [DOI: 10.1016/S0168-8278(16)00174-4]

186 **Petrasek J**, Bala S, Csak T, Lippai D, Kodys K, Menashy V, Barrieau M, Min SY, Kurt-Jones EA, Szabo G. IL-1 receptor antago­nist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. *J Clin Invest* 2012; **122**: 3476-3489 [PMID: 22945633 DOI: 10.1172/JCI60777]

187 **Tkachenko P**, Maevskaya M, Pavlov A, Komkova I, Pavlov C, Ivashkin V. Prednisolone plus S-adenosil-L-methionine in severe alcoholic hepatitis. *Hepatol Int* 2016; **10**: 983-987 [PMID: 27337960 DOI: 10.1007/s12072-016-9751-4]

188 **Váli L**, Blázovics A, Fehér J. [The therapeutic effect of metadoxine on alcoholic and non-alcoholic steatohepatitis]. *Orv Hetil* 2005; **146**: 2409-2414 [PMID: 16398154]

189 **Higuera-de la Tijera F**, Servín-Caamaño AI, Cruz-Herrera J, Serralde-Zúñiga AE, Abdo-Francis JM, Gutiérrez-Reyes G, Pérez-Hernández JL. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. *Ann Hepatol* 2016; **13**: 343-352 [PMID: 24756009]

190 **Higuera-de la Tijera F**, Servín-Caamaño AI, Serralde-Zúñiga AE, Cruz-Herrera J, Pérez-Torres E, Abdo-Francis JM, Salas-Gordillo F, Pérez-Hernández JL. Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis. *World J Gastroenterol* 2015; **21**: 4975-4985 [PMID: 25945012 DOI: 10.3748/wjg.v21.i16.4975]

191 **US National Institutes of Health**. Search of: ELADTM liver/Exclude Unknown - List Results - ClinicalTrials.gov. [cited 2016 Jun 1]. Available from: URL: https://clinicaltrials.gov/ct2/results?term=ELADTM liver&no\_unk=Y

192 **Clinical Trials**. Vital Therapies [Internet]. Available from: URL: http://vitaltherapies.com/clinical-trials/

193 **Lazaro R**, Wu R, Lee S, Zhu NL, Chen CL, French SW, Xu J, Machida K, Tsukamoto H. Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice. *Hepatology* 2015; **61**: 129-140 [PMID: 25132354 DOI: 10.1002/hep.27383]

194 **Mandrekar P**, Bataller R, Tsukamoto H, Gao B. Alcoholic hepatitis: Translational approaches to develop targeted therapies. *Hepatology* 2016; **64**: 1343-1355 [PMID: 26940353 DOI: 10.1002/hep.28530]

195 **Gao B**, Shah VH. Combination therapy: New hope for alcoholic hepatitis? *Clin Res Hepatol Gastroenterol* 2015; **39** Suppl 1: S7-S11 [PMID: 26193867 DOI: 10.1016/j.clinre.2015.05.008]

196 **Moreau R**, Arroyo V. Acute-on-chronic liver failure: a new clinical entity. *Clin Gastroenterol Hepatol* 2015; **13**: 836-841 [PMID: 24583872 DOI: 10.1016/j.cgh.2014.02.027]

197 **Moreau R**, Jalan R, Arroyo V. Acute-on-Chronic Liver Failure: Recent Concepts. *J Clin Exp Hepatol* 2015; **5**: 81-85 [PMID: 25941435 DOI: 10.1016/j.jceh.2014.09.003]

Figure Legends

****

**Figure 1 Ethanol metabolism in the hepatocyte.** 1Ethanol inhibits the peroxisome-proliferator-activated receptor  and adenosine monophosphate activated protein kinase with stimulation of sterol regulatory element binding protein 1, a membrane bound transcript factor to promote lipogenesis. ADH: Alcohol dehydrogenase; ALDH: Aldehyde dehydrogenase; NADH: Nicotinamide adenine dinucleotide.

****

**Figure 2 Acetaldehyde induced gut permeability with endotoxemia and inflammatory cascade.** LPS: Lipopolysaccharide; TLR-4: Toll-like receptor type 4; ROS: Reactive oxygen species; NADPH: Nicotinamide adenine dinucleotide phosphate-oxidase; NFKB: Nuclear factor kappa beta; JNK: c-Jun N-terminal kinase; AP-1: Activator protein 1; ICAM-1: Intracellular adhesion molecule 1; VCAM-1: Vascular adhesion protein 1; IL-8: Interleukin 8; CCL 2: C-C motif ligand; TNF: Tumor necrosis factor alpha; IL-1: Interleukin 1; IL-6: Interleukin 6.

Footnotes

Conflict-of-interest statement:In regards to affiliations, Phoenix Fung and Nikolaos Pyrsopoulos perform research for Vital Therapies and Gilead Sciences. Nikolaos Pyrsopoulos is a member of the scientific advisory board for Vital Therapies and advisory board for Gilead.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Peer-review started: December 6, 2016

First decision:January 16, 2017

Article in press: March 13, 2017

**P- Reviewer**: Dhanda A, Singal AK, Thieringer J **S- Editor**:Ji FF **L- Editor**: A **E- Editor**:Li D

**Table 1 New potential treatments for alcoholic hepatitis**

|  |  |  |
| --- | --- | --- |
| Treatment | Class | Mechanism of action |
| Probiotics | Gut microbiota modification | Reduction of bacterial endotoxins and translocation |
| IL-22 recombinant protein | Immune modulation | Hepatoprotective: Antioxidant, apoptotic, proliferative, and antimicrobial properties |
| G-CSF | Growth factor | Liver regeneration |
| Obeticholic acid | Farnesoid X receptor | Improvement in cholestasis |
| Emricasan | Caspase inhibitor | Apoptosis, inflammation, and fibrosis inhibitor |
| Anakinra (Pentoxifylline + Zinc) | IL-1 receptor | Decreases hepatic inflammation |
| SAMe | Glutathione precursor | Decreases oxidative stress |
| Metadoxine | Antioxidant | Decreases oxidative stress and steatosis |
| ELAD | Extracorporeal human hepatic cell-based liver treatment | Toxin removal, reduction of inflammation, liver regeneration |

IL: Interleukin; G-CSF: Granulocyte colony-stimulating factor; ELAD: Extracorporeal liver assist device; SAMe: S-adenosil-L-methionine.